CA2352466A1 - Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof - Google Patents

Abstract

The present invention is directed to the cloning, sequencing and expression of homologous immnunoreactive 28-kDa protein genes, ECa28-1 and ECa28SA3, from a polymorphic multiple gene family of Ehrlichia canis. A complete sequence of another 28-kDa protein gene, ECaSA2, is also provided. Further disclosed is a multigene locus encoding all five homologous 28-kDa protein genes of Ehrlichia canis. Recombinant Ehrlichia canis 28-kDa proteins react with convalescent phase antiserum from an E. canis-infected dog.

Description

GENES OF EHRLICHIA CAN.IS AND USES THEREOF
S
BACKGROUND OF THE INVENTION
Fi~ld of y~e_. TnvPnti~n The present invention relates generally to the field o f molecular biology. More specifically, the present invention relates t o molecular cloning and characterization of homologous 28-kDa protein genes in Ehrlichia canis and a multigene locus encoding the 28-kDa homologous proteins of Ehrlichia cams and uses thereof.
Description ~f the Rel~teri Ar Canine ehrlichiosis, also known as canine tropical pancytopenia, is a tick-borne rickettsial disease of dogs first described in Africa in 1935 and the United States in 1963 (Donatien and Lestoquard, 1935; Ewing, 1963). The disease became better recognized after an epizootic outbreak occurred in United S fates military dogs during the Vietnam War (Walker et al., 1970) The etiologic agent of canine ehrlichiosis is Ehrlichia canis, a small, gram-negative, obligate intracellular bacterium which exhibits tropism for mononuclear phagocytes (Nyindo er al., 197 / ) and is transmitted by the brown dog tick, Rhipiceplaalus sangecineccs (Groves et al., /975). The progression of canine ehrlichiosis occurs in three phases, acute, subclinical and chronic. The acute phase is characterized by fever, anorexia, depression, lymphadenopathy and mild thrombocytopenia (Troy and Forrester, 1990). Dogs typically recover from the acute phase, but become persistently infected carriers of the organism without clinical signs of disease for months or even years (Harrus et al., 1998). A chronic phase develops i n some cases that is characterized by thrombocytopenia, hyperglobulinemia, anorexia, emaciation, and hemorrhage, particularly epistaxis, followed by death (Troy and Forrester, 1990).
Molecular taxonomic analysis based on the 16S rRNA gene has determined that E. canis and E. chaffeens is, the etiologic agent o f human monocytic ehrlichiosis (HME), are closely related (Anderson a t al., 1991; Anderson et al., 1992; Dawson et al.; I991; Chen et al., 1994). Considerable cross reactivity of the 64, 47, 40, 30, 29 and 2 3 -kDa antigens between E. canis and E. chaffeensis has been reported (Chen et al., 1994; Chen et al., 1997; Rikihisa et al., 1994; Rikihisa a t al., 1992). Analysis of immunoreactive antigens with human and canine convalescent phase sera by immunobIot has resulted in tha identification of numerous immunodominant proteins of E. cahis, including a 30-kDa protein (Chen et al., 1997). In addition, a 30-kDa protein of E. canis has been described as a major immunodominant antigen recognized early in the immune response that is antigenically distinct from the 30-kDa protein of E. chaffeensis {Rikihisa et al., 1992; Rikihisa et al., 1994). Other immunodominant proteins of E
canis with molecular masses ranging from 20 to 30-kDa have also been identified {Brouqui et al., 1992; Nyindo et al., 1991; Chen et al., 1994; Chen et al., 1997).
Recently, cloning and sequencing of a multigene family (omp-1 ) encoding proteins of 23 to 28-kDa have been described for E
chaffeensis (Ohashi et al., 1998). The 28-kDa immunodominant outer membrane protein gene (p28) of E. chaffeensis, homologous to the Cowdria racmiraantium map-1 gene, was cloned. Mice immunized with recombinant P28 were protected against challenge infection with the WO 00132745 PCT/US99/280?5 homologous strain according to PCR analysis of periperal blood 5 days after challenge (Ohashi et al., 1998). Molecular cloning of two similar, but nonidentical, tandernly arranged 28-kDa genes of E. canis homologous to E. chaffeensis omp-I gene family and C. rumanintium rnap- I gene has also been reported (Reddy et al., 1998).
The prior art is deficient in the lack of cloning and characterization of new homologous 28-kDa immunoreactive protein genes of Ehrlichia canis and a single multigene locus containing the homologous 28-kDa protein genes. Further, The prior art is deficient in the lack of recombinant proteins of such immunoreactive genes of Ehrlichia canis. The present invention fulfills this long-standing need and desire in the art.
SUMMARY OF THE INVENTION
The present invention describes the molecular cloning, sequencing, characterization, and expression of homologous mature 28-kDa immunoreactive protein genes of Ehrlichia canis (designated Eca28-l, ECa28SA3 and ECa28SA2), and the identification of a single locus (5.592-kb) containing five 28-kDa protein genes of Ehrlichia cams (ECa28SAl, ECa28SA2, ECa28SA3, Eca28-I and ECa28-2).
Comparison with E. chaffeensis and among E. canis 28-kDa protein genes revealed that ECa28-1 shares the most amino acid homology with the E. chaffeensi,r ornp-I multigene family and is highly conserved among E. cams isolates. The five 28-kDa proteins were predicted t o have signal peptides resulting in mature proteins, and had amino acid homology ranging from Si to 72%. Analysis of intergenic regions revealed hypothetical promoter regions for each gene, suggesting that these genes may be independently and differentially expressed.

3 0 Intergenic noncoding regions ranged in size from 299 to 355-bp, a n d were 48 to 71 % homologous.
In one embodiment of the present invention, there are provided DNA sequences encoding a 30-kDa immunoreactive protein of Ehrlichia canis. Preferably, the protein has an amino acid sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6, and the gene has a nucleic acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5 and is a member of a polymorphic multiple gene family. Generally, the protein has an N-terminal signal sequence which is cleaved after i0 post-translational process resulting in the production of a mature 28-kDa protein. Still preferably, the DNAs encoding 28-kDa proteins are contained in a single multigene locus, which has the size of 5.592 k b and encodes all five homologous 28-kDa proteins of Ehrlichia canis.
In another embodiment of the present invention, there is provided an expression vector comprising a gene encoding a 28-kDa immunoreaetive protein of Ehrlichia canis and capable of expressing the gene when the vector is introduced into a cell.
In still another embodiment of the present invention, there is provided a recombinant protein comprising an amino acid s a q a a n c a selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 a n d SEQ ID No. 6. Preferably, the amino acid sequence is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID
No. 1, SEQ ID No. 3 and SEQ ID No. 5. Preferably, the recombinant protein comprises four variable regions which are surface exposed, hydrophilic and antigenic. The recombinant protein may be useful as an antigen.
In yet another embodiment of the present invention, there is provided a method of producing the recombinant protein, comprising the steps of obtaining a vector that comprises a n expression region comprising a sequence encoding the amino acid sequence selected from the group consisting of SEQ ID No. 2. SEQ ID
Na. 4 and SEQ ID No. 6 operatively linked to a promoter; transfecting the vector into a cell; and culturing the cell under conditions effective for expression of the expression region.
The invention may also be described in certain embodiments as a method of inhibiting Ehrlichia canis infection in a subject comprising the steps of: identifying a subject suspected o f being exposed to or infected with Ehrlichia canis; and administering a composition comprising a 28-kDa antigen of Ehrlichia canis in a n amount effective to inhibit an Ehrlichia canis infection. The inhibition may occur through any means such as, i.e. the stimulation of the subject's humoral or cellular immune responses, or by other means such as inhibiting the normal function of the 28-kDa antigen, or even competing with the antigen for interaction with some agent in th a subject's body.
Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, m o r a particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part o f the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.
Figure i shows nucleic acid sequence (SEQ ID No. 1 ) a n d deduced amino acid sequence (SEQ ID No. 2) of ECa28-I gene including adjacent 5' and 3' non-coding sequences. The ATG start colon and TAA termination are shown in bold, and the 23 amino acid leader signal sequence is underlined.
Figure 2 shows SDS-PAGE of expressed 50-kDa recombinant ECa28-1-thioredoxin fusion protein (Lane l, arrow) and 16-kDa thioredoxin control (Lane 2, arrow), and corresponding immunoblot of recombinant ECa28-1-thioredoxin fusion protein recognized by covalescent-phase E. canis canine antiserum (Lane 3 ) .
Thiroredoxin control was not detected by E.canis antiserum ( n o t shown).
Figure 3 shows alignment of ECa28-1 protein (SEQ ID NO.
2), and ECa28SA2 (partial sequence, SEQ ID NO. 7) and ECa28SA 1 (SEQ
ID NO. 8), E. chaffeensis P28 (SEQ ID NO. 9}, E. chaffeensis OMP-1 family (SEQ ID NOs: 10-14) and C. ruminantium MAP-1 (SEQ ID NO.
15) amino acid sequences. The ECa28-1 amino acid sequence is presented as the consensus sequence. Amino acids not shown are identical to ECa28-1 and are represented by a dot. Divergent amino acids are shown with the corresponding one letter abbreviation. Gaps introduced for maximal alignment of the amino acid sequences are denoted with a dash. Variable regions are underlined and denoted (VR1, VR2, VR3, and VR4). The arrows indicate the predicted signal peptidase cleavage site for the signal peptide.
Figure 4 shows phylogenetic relatedness of E. canis ECa28-1 with the ECa28SA2 (partial sequence) and ECa28SA1, 6 members of the E.chaffeensis omp-I multiple gene family, and C. rumanintium map-I from deduced amino acid sequences uxilizing unbalanced tree WO 00/32745 PCT/US99/2$075 construction. The length of each pair of branches represents the distance between the amino acid sequence of the pairs. The scale measures the distance between sequences.
Figure 5 shows Southern blot analysis of E. canis genomic DNA completely digested with six individual restriction enzymes a n d hybridized with a ECa28-1 DIG-labeled probe (Lanes 2-7); DIG-labeled molecular weight markers {Lanes. 1 and 8).
Figure 6 shows comparison of predicted protein characteristics of ECa28-1 (Jake strain) and E. chaffeensis P28 (Arkansas strain). Surface probability predicts the surface residues by using a window of hexapeptide. A surface residue is any residue with a >2.0 nmz of water accessible surface area. A hexapeptide with a value higher than 1 was considered as surface region. The antigenic index predicts potential antigenic determinants. The regions with a value above zero are potential antigenic determinants. T-cell motif locates the potential T-cell antigenic determinants by using a motif o f 5 amino acids with residue 1-glycine or polar, residue 2-hydrophobic, residue 3-hydrophobic, residue 4-hydrophobic or proline, and residue 5-polar or glycine. The scale indicates amino acid positions.
Figure 7 shows nucleic acid sequences and deduced amino acid sequences of the E. canis 28-kDa protein genes ECa28SA2 (nucleotide 1-849: SEQ ID No. 3; amino acid sequence: SEQ ID No. 4 ) and ECa28SA3 (nucleotide 1195-2031: SEQ ID No. S; amino acid sequence: SEQ ID No. 6) including intergenic noncoding sequences 2 5 (NC2, nucleotide 850-1194: SEQ ID No. 31 ). The ATG start codon a n d termination condons are shown in bold.
Figure 8 shows schematic of the five E. canis 28-kDa protein gene locus (5.592-Kb) indicating genomic orientation a n d intergenic noncoding regions (28NC1-4). The 28-kDa protein genes shown in Locus 1 and 2 (shaded} have been described (McBride et al., WO 00/32745 PCT/t1S99/28075 1999; Reddy et al., 1998: Ohashi et al., 1998 ). The complete s a q a a n c a of ECaSA2 and a new 28-kDa protein gene designated (ECa28SA3 unshaded) was sequenced. The noncoding intergenic regions (28NC2-3) between ECaSA2. ECa28SA3 and ECa28-I were completed joining the previously unlinked loci 1 and 2.
Figure 9 shows phylogenetic relatedness of the five E
canis 28-kDa protein gene members based on amino acid sequences utilizing unbalanced tree construction. The length of each pair of branches represents the distance between amino acid pairs. The scale measures the distance beteween sequences.
Figure 14 shows alignment of E. canis 28-kDa protein gene intergenic noncoding nucleic acid sequences (SEQ ID Nos. 30-33). Nucleic acids not shown, denoted with a dot (.), are identical t o noncoding region 1 (28NC 1 ). Divergence is shown with t h a corresponding one letter abbreviation. Gaps introduced for maximal alignment of the amino acid sequences are denoted with a dash (-).
Putative transcriptional promoter regions (-10 and -35) and ribosomal binding site (RBS) are boxed.
DETAILED DESCRIPTION OF THE INVENTION
The present invention describes cloning, sequencing and expression of homologous genes encoding a 30-kilodalton (kDa) protein of Ehrlichia canis. A comparative molecular analysis of homologous genes among seven E. cams isolates and the E. chaffeensis omp-1 multigene family was also performed. Two new 28-kDa protein genes are identified, ECa28-1 and ECa28SA3. ECa28-1 has an 834-by open reading frame encoding a protein of 278 amino acids (SEQ ID
No. 2) with a predicted molecular mass of 30.5-kDa. An N-terminal signal sequence was identified suggesting that the protein is post-WO 00132745 PCTlUS99/2$075 translationally modified to a mature protein of 27.7-kDa. ECa28SA3 has an 840-by open reading frame encoding a 280 amino acid protein (SEQ ID No. 6).
Using PCR to amplify 28-kDa protein genes of E. canis, a previously unsequenced region of Eca28SA2 was completed. Sequence analysis of ECa28SA2 revealed an 849-by open reading frame encoding a 283 amino acid protein (SEQ ID Na. 4): PCR amplification using primers specific for 28-kDa protein gene intergenic noncoding regions linked two previously separate Ioci, identifying a single locus (5.592 kb) containing alI five 28-kDa protein genes. The five 28-kDa proteins were predicted to have signal peptides resulting in mature proteins, and had amino acid homology ranging from 51 to 72%.
Analysis of intergenic regions revealed hypothetical promoter regions for each gene, suggesting that these genes may be independently a n d differentially expressed. Intergenic noncoding regions (28NC1-4) ranged in size from 299 to 355-bp, and were 48 to 71 % homologous.
The present invention is directed to two new homologous 28-kDa protein genes in Elzrlichia canis, Eca28-1 and ECa28SA3, and a complete sequence of previously partially sequenced ECa28SA2. Also disclosed is a multigene locus encoding all five homologous 28-kDa outer membrane proteins of Ehrlichia canis.
In one embodiment of the present invention, there are provided DNA sequences encoding a 30-kDa immunoreactive protein of Ehrlichia canis. Preferably, the protein has an amino acid s a qu a nc a selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6, and the gene has a nucleic acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5 and is a member of a polymorphic multiple gene family. More preferably, the protein has an N-terminal signal sequence which is cleaved after post-translational process resulting in the production o f a mature 28-kDa protein. Still preferably, the DNAs encoding 28-kDa proteins are contained in a single multigene Iocus, which has the size of 5.592 kb and encodes alI five homologous 28-kDa proteins o f Ehrlichia canis.
S In another embodiment of the present invention, there i s provided an expression vector comprising a gene encoding a 28-kDa immunoreactive protein of Ehrlichia cams and capable of expressing the gene when the vector is introduced into a cell.
In still another embodiment of the present invention, there is provided a recombinant protein comprising an amino acid sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ iD No. 6. Preferably, the amino acid sequence is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID
No. I , SEQ iD No. 3 and SEQ ID No. 5. Preferably, the r a c o m b i n a n t I S protein comprises four variable regions which are surface exposed, hydrophilic and antigenic. Still preferably, the recombinant protein is an antigen.
In yet another embodiment of the present invention, there is provided a method of producing the recombinant protein, comprising the steps of obtaining a vector that comprises a n expression region comprising a sequence encoding the amino acid sequence selected from the group consisting of SEQ ID No. 2, SEQ ID
No. 4 and SEQ ID No. 6 operatively linked to a promoter; transfecting the vector into a cell; and culturing the cell under conditions effective for expression of the expression region.
The invention may also be described in certain embodiments as a method of inhibiting Ehrlichia canis infection in a subject comprising the steps of: identifying a subject suspected o f being exposed to or infected with Ehrlichia cams; and administering a 34 composition comprising a 28-kDa antigen of Ehrlichia cams in a n Io amount effective to inhibit nn Ehrlichiu cunis infection. The inhibition may occur through any means such as, i.e. the stimulation of the subject's humoral or cellular immune responses, or by other means such as inhibiting the normal function of the 28-kDa antigen, or even competing with the antigen for interaction with some agent in t h a subject's body.
In accordance with the present invention there may b a employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Maniatis, Fritsch & Sambrook, "Molecular Cloning: A Laboratory Manual ( 19 8 2 ) ;
"DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed.
1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" [B.D. Homes & S.J. Higgins eds. (1985)]; "Transcription and Translation" [B.D. Homes & S.J. Higgins eds. (1984)]; "Animal Cell Culture" [R.I. Freshney, ed. ( 1986)]; "Immobilized Cells And Enzymes"
[IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning"
( 1984).
Therefore, if appearing herein, the following terms shall have the definitions set out below.
A "replicon" is. any genetic element (e:g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA
replication in vivo; i.e., capable of replication under its own control.
A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.
A "DNA molecule" refers to the polymeric form o f deoxyribonucleatides (adenine, guanine, thymine, or cytosine) in its either single stranded . form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, WO 00/32745 PCTlLJS99l28075 and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter olio, in linear DNA
molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure herein according to tha normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).
A DNA "coding sequence" is a double-stranded DNA
sequence which is transcribed and translated into a polypeptide i n vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined b y a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.
Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylatian signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.
A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3 ' terminus by the transcription initiation site and extends upstream ( 5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiationsite, as well protein binding domains as (consensus sequences)responsible for the binding of RNA

polymerase. Eukaryoticpromoters often, but not always, contain "TATA" boxes and "CAT" boxes. Prokaryoticpromoters contain Shine-S Dalgarno seq uences addition to the -10 and -3S consensus in sequences.

An "expression control sequence" is a DNA sequence that controls and regulates Ehe transcription and translation of another DNA sequence. A coding sequence is "under the control" o f transcriptional and translational control sequences in a cell when RNA
polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.
A "signal sequence" can be included near the coding sequence. This sequence encodes a signal peptide, N-terminal to the 1 S polypeptide, that communicates to the host cell to direct th a polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before th a protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes.
The term "oligonucleotide", as used herein in referring to the probe of the present invention, is defined as a molecule comprised o f two or more ribonucleotides, preferably more than three. its exact size will depend upon many factors which, in turn, depend upon t h a ultimate function and use of the oligonucleotide.
The term "primer" as used herein refers to a n oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions i n which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the i3 WO 00/32745 PCTlUS99/28075 presence of nucleotides and an inducing agent such as a DNA
polymerase and at a suitable temperature and pH. The primer may b a either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and use the method. For example, for diagnostic applications, depending on the complexity of the target sequence, t h a oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides.
The primers herein are selected to be "substantially"
complementary to different strands of a particular target DNA
sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, i5 the primer sequence need not reflect the exact sequence of tha template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence or hybridize therewith and thereby form the template for the synthesis of the extension product.
A cell has been "transformed" by exogenous o r heteroIogous DNA when such DNA has been introduced inside the cell.
The transforming DNA may or may not be integrated {covalently linked) into the genome of the cell. In prokaryotes, yeast, a n d mammalian cells for example, the transforming DNA may b a maintained on an episornal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication.
This stability is demonstrated by the ability of the eukaryotic cell t o establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population o f cells derived from a single cell or ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth in vitro for many generations.
Two DNA sequences are "substantially homologous" when at least about 75% {preferably at least about 80%, and most preferably at Ieast about 90% or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing th a sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis et al., supra; DNA Cloning, Vols. I & II, supra; Nucleic Acid Hybridization, supra.
A "heterolagous' region of the DNA construct is a n identifiable segment of DNA within a larger DNA molecule that is n o t found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genorne of the source organism. In another 2S example, coding sequence is a construct where the coding sequence itself is not found in nature {e.g., a cDNA where the genomic coding sequence contains introns, or synthetic sequences having c o d o n s different than the native gene). Allelic variations or naturally occurring mutational events do not give rise to a heterologaus region 3 0 of DNA as defined herein.

The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to untraviolet Iight, and others. A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate.
Proteins can also be labeled with a radioactive element o r with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from 3H, 1~C, 32P, 3sS, ~~Cl, S~Cr, S~Co, SgCo, 59Fe, 9aY, I25I, 131I, and ~86Re.
Enzyme labels are likewise useful, and can be detected b y any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotornetric, amperometric or gasometric techniques.
The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used i n these procedures are known and can be utilized. The preferred are peroxidase, (3-glucuronidase, ~i-D-glucosidase, ~3-D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase.
U.S. Patent Nos. 3,654,090, 3,850,752, and 4,016,043 are referred t o by way of example for their disclosure of alternate labeling material and methods.
As used herein, the term "host" is meant to include n o t only prokaryotes but also eukaryotes such as yeast, plant and animal cells. A recombinant DNA molecule or gene which encodes a 28-kDa immunoreactive protein of Ehrlichia cahis of the present invention can be used to transform a host using any of the techniques commonly known to those of ordinary skill in the art. Especially preferred is the use of a vector containing coding sequences for a gene encoding a 28-kDa immunoreactive protein of Ehrlichia canis of the present invention for purposes of prokaryote transformation.
Prokaryotic hosts may include E. coli, S. tymphimurium, Serratia marcescens and Bacillus subtilis. Eukaryotic hosts include yeasts such as Pichia pastoris, mammalian cells and insect cells.
In general, expression vectors containing promoter sequences which facilitate the efficient transcription of the inserted DNA fragment are used in connection with the host. The expression vector typically contains an origin of replication, promoter(s), terminator(s), as well as specific genes which are capable of providing phenotypic selection in transformed cells. The transformed hosts can I 5 be fermented and cultured according to means known in the art t o achieve optimal cell growth.
The invention includes a substantially pure DNA encoding a 28-kDa immunoreactive protein of Ehrlichia canis, a strand of which DNA will hybridize at high stringency to a probe containing a sequence of at least 15 consecutive nucleotides of SEQ ID Na. 1 or SEQ
ID No. 3 or SEQ ID No. 5. The protein encoded by the DNA of this invention may share at least 80% sequence identity (preferably 85 %, more preferably 90%, and most preferably 95%) with the amino acids listed in SEQ ID No. 2 or SEQ ID No. 4 or SEQ ID No. 6. M o r a preferably, the DNA includes the coding sequence of the nucleotides of SEQ ID No. i or SEQ ID No. 3 or SEQ ID No. 5, or a degenerate variant of such a sequence.
The probe to which the DNA of the invention hybridizes preferably consists of a sequence of at least 20 consecutive nucleotides, more preferably 40 nucleotides, even more preferably 5 0 nucleotides, and most preferably 100 nucleotides or more (up t o 100%) of the coding sequence of the nucleotides listed in SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 5 or the complement thereof. Such a probe is useful for detecting expression of the 28-kDa immunoreactive protein of Ehrlichia canis in a human cell by a method including the steps of (a) contacting mRNA obtained from the cell with the labeled hybridization probe; and {b) detecting hybridization of the probe with the mRNA.
This invention also includes a substantially pure DNA
containing a sequence of at least 15 consecutive nucleotides (preferably 20, more preferably 30, even more preferably 50, a n d most preferably all) of the region from the nucleotides listed in SEQ ID
No 1 or SEQ ID No. 3 or SEQ ID No. 5.
By "high stringency" is meant DNA hybridization and wash conditions characterized by high temperature and low salt concentration, e.g., wash conditions of 65°C at a salt concentration o f approximately 0.1 x SSC, or the functional equivalent thereof. For example, high stringency conditions may include hybridization a t about 42°C in the presence of about 50% formamide; a first wash a t about 65°C with about 2 x SSC containing 1% SDS; followed by a second wash at about 65°C with about 0.1 x SSC.
By "substantially pure DNA" is meant DNA that is not p a r t of a milieu in which the DNA naturally occurs, by virtue of separation {partial or total purification) of some or all of the molecules of that milieu, or by virtue of alteration of sequences that flank the claimed DNA. The term therefore includes, for example, a recombinant DNA
which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote o r eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by polymerase chain reaction WO 00132745 PCT/US99/2$075 (PCR) or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence, e.g., a fusion protein. Also included is a recombinant DNA which includes a portion of the nucleotides listed in SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No.
5 which encodes an alternative splice variant of a gene encoding a 28-kDa immunoreactive protein of Ehrlichia canis.
The DNA may have at least about 70% sequence identity t o the coding sequence of the nucleotides listed in SEQ ID No. 1 or SEQ ID
l 0 No. 3 or SEQ ID No. 5, preferably at least 75% (e.g. at least 80%); a n d most preferably at least 90%. The identity between two sequences is a direct function of the number of matching or identical positions.
When a subunit position in both of the two sequences is occupied b y the same monomeric subunit, e.g., if a given position is occupied by an adenine in each of two DNA molecules, then they are identical a t that position. For example, if 7 positions in a sequence 10 nucleotides in length are identical to the corresponding positions in a second 10-nucleotide sequence, then the two sequences have 70%
sequence identity. The length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 100 nucleotides. Sequence identity is typically measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705).
The present invention comprises a vector comprising a DNA sequence coding for a which encodes a gene encoding a 28-kDa immunoreactive protein of Ehrlichia canis and said vector is capable of replication in a host which comprises, in operable linkage: a) a n origin of replication; b) a promoter; and c) a DNA sequence coding for said protein. Preferably, the vector of the present invention contains a portion of the DNA sequence shown in SEQ ID No. I or SEQ
ID No. 3 or SEQ ID No. 5.
A "vector" may be defined as a repiicable nucleic acid construct, e.g., a plasmid or viral nucleic acid. Vectors may be a s ed to amplify and/or express nucleic acid encoding a 28-kDa immunoreactive protein of Ehrlichia canis. An expression vector is a replicable construct in which a nucleic acid sequence encoding a polypeptide is operably linked to suitable control sequences capable of effecting expression of the polypeptide in a cell. The need for s a c h control sequences will vary depending upon the cell selected and th a transformation method chosen. Generally, control sequences include a transcriptional promoter and/or enhances, suitable mRNA ribosomal binding sites, and sequences which control the termination of I 5 transcription and translation. Methods which are well known to th o s a skilled in the art can be used to construct expression vectors containing appropriate transeriptional and translational control signals. See for example, the techniques described in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual (2nd Ed.), Cold Spring Harbor Press, N.Y. A gene and its transcription control sequences are defined as being "operably linked" if the transcription control sequences effectively control the transcription of the gene. Vectors o f the invention include, but are not limited to, plasmid vectors and viral vectors. Preferred viral vectors of the invention are those derived from retroviruses, adenovirus, adeno-associated virus, SV40 virus, o r herpes viruses.
By a "substantially pure protein" is meant a protein which has been separated from at least some of those components which naturally accompany it. Typically, the protein is substantially pure 3 0 when it is at least 60%, by weight, free from the proteins and o th a r naturally-occurring organic molecules with which it is naturally associated in vivo. Preferably, the purity of the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight. A substantially pure 28-kDa immunoreactive protein o f S Ehrlichia cams may be obtained, for example, by extraction from a natural source; by expression of a recombinant nucleic acid encoding a 28-kDa immunoreactive protein of Ehrlichia canis; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, e.g., column chromatography such as immunoaffinity chromatography using an antibody specific for a 28-kDa immunoreactive protein of Ehrlichia canis, polyacrylamide gel electrophoresis, or HPLC analysis. A protein is substantially free o f naturally associated components when it is separated from at least some of those contaminants which accompany it in its natural state.
Thus, a protein which is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be, by definition, substantially free from its naturally associated components. Accordingly, substantially pure proteins include eukaryotic proteins synthesized in E. coli, .other prokaryotes, or any other organism in which they do not naturally occur.
In addition to substantially full-length proteins, the invention also includes fragments {e.g., antigenic fragments} of the 28-kDa immunoreactive protein of Ehrlichia cams (SEQ ID No. 2 o r SEQ ID No. 4 or SEQ ID No. 6). As used herein, "fragment," as applied to a polypeptide, will ordinarily be at Ieast 10 residues, more typically at least 20 residues, and preferably at least 30 (e.g., 50) residues in length, but less than the entire, intact sequence. Fragments of the 2 8 -kDa immunoreactive protein of Ehrlichia canis can be generated by methods known to those skilled in the art, e.g., by enzymatic digestion of naturally occurring or recombinant 28-kDa immunoreactive protein of Ehrlichia canis, by recombinant DNA techniques using a n expression vector that encodes a defined fragment of 28-kDa immunoreactive protein of Ehrlichia canis, or by chemical synthesis.
The ability of a candidate fragment to exhibit a characteristic of 28-kDa immunoreactive protein of Ehrlichia canis {e.g., binding to a n antibody specific for 28-kDa immunoreactive protein of Ehrlichia canis) can be assessed by methods described herein. Purified 28-kDa immunoreactive protein of Ehrlichia cams or antigenic fragments of 28-kDa immunoreactive protein of Ehrlichia canis can be used t o generate new antibodies or to test existing antibodies (e.g., as positive controls in a diagnostic assay) by employing standard protocols known to those skilled in the art. Included in this invention are polyclonal antisera generated by using 28-kDa immunoreactive protein of Ehrlichia canis or a fragment of 28-kDa immunoreactive protein of Ehrlichia canis as the immunogen in, e.g., rabbits. Standard protocols for monoclonal and polyclonal antibody production known to those skilled in this art are employed. The monoclonal antibodies generated by this procedure can be screened for the ability to identify recombinant Ehrlichia canis cDNA clones, and to distinguish them from known cDNA clones.
Further included in this invention are fragments of the 2 8 -kDa immunoreactive protein of Ehrlichia canis which are encoded at least in part by portions of SEQ ID No. 1 or SEQ ID No. 3 or SEQ m No.
5, e.g., products of alternative mRNA splicing or alternative protein processing events, or in which a section of the sequence has been deleted. The fragment, or the intact 28-kDa immunoreactive protein of Ehrlichia canis, may be covalently linked to another polypeptide, e.g. which acts as a label, a ligand or a means to increase antigenicity.
The phrase "pharmaceutically acceptable" refers t o 3 0 molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human. The preparation of an aqueous composition that contains a protein as a n active ingredient is well understood in the art. Typically, s a c h compositions are prepared as injectables, either as liquid solutions o r suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be emulsified.
A protein may be formulated into a composition in a neutral or salt forma Pharmaceutically acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, f o r example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine;
trimethylamine, histidine, procaine and the like.
Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such am o a n t as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as injectable solutions.
For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
2S These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage could be dissolved in 1 mL of isotonic NaCl solution and either added to 1000mL of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
As is well known in the art, a given polypeptide may vary in its immunogenicity. It is often necessary therefore to couple the immunogen (e.g., a polypeptide of the present invention) with a carrier. Exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and human serum albumin. Other carriers may include a variety of lymphokines and adjuvants such as IL2, IL4, IL8 and others.
Means for conjugating a polypeptide to a carrier protein are well known in the art and include glutaraldehyde, m -maleimidobenzoyl-N-hydroxysuccinimide ester, carbo-diimide and bis-biazotized benzidine, It is also understood that the peptide may be conjugated to a protein by genetic engineering techniques that axe well known in the art.
As is also well known in the art, immunogenicity to a particular immunogen can be enhanced by the use of non-specific stimulators of the immune response known as adjuvants. Exemplary and preferred adjuvants include complete BCG, Detox, {RIBI, Immunochem Research Inc.) ISCOMS and aluminum hydroxide adjuvant {Superphos, Biosector).
As used herein the term "complement" is used to define the strand of nucleic acid which will hybridize to the first nucleic acid sequence to form a double stranded molecule under stringent conditions. Stringent conditions are those that allow hybridization between two nucleic acid sequences with a high degree of homology, but precludes hybridization of random sequences. For example, hybridization at low temperature and/or high ionic strength is t a r m a d low stringency and hybridization at high temperature andlor low ionic strength is termed high stringency. The temperature and ionic strength of a desired stringency are understood to be applicable t o particular probe lengths, to the length and base content of the sequences and to the presence of formamide in the hybridization mixture.
As used herein, the term "engineered" or "recombinant"
cell is intended to refer to a cell into which a recombinant gene, s a c h as a gene encoding an Ehrlichia chaffeensis antigen has been introduced. Therefore, engineered cells are distinguishable from naturally occurring cells which do not contain a recombinantly introduced gene. Engineered cells are thus cells having a gene o r genes introduced through the hand of man. Recombinantly introduced genes will either be in the form of a cDNA gene, a copy o f a genomic gene, or will include genes positioned adjacent to a promoter not naturally associated with the particular introduced gene. In addition, the recombinant gene may be integrated into the host genome, or it may be contained in a vector, or in a bacterial genome transfected into the host cell.
The following examples are given for the purpose o f illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.
Ehrlichiae and Purificati~~
Ehrlichia canis (Florida strain and isolates Dernon, DJ, Jake, and Fuzzy) were provided by Dr. Edward Breitschwerdt, (College of Veterinary Medicine, North Carolina State University, Raleigh, NC).
E. canis (Louisiana strain) was provided by Dr. Richard E. Corstvet (School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA) and E. canis (Oklahoma strain) was provided by Dr.
S - Jacqueline Dawson {Centers for Disease Control and Prevention, Atlanta, GA). Propagation of ehrlichiae was performed in DH82 cells with DMEM supplemented with 10% bovine calf serum and 2 mM L-glutaminc at 37°C. The intracellular growth in DH82 cells was monitored by presence of E cams morulae using general cytologic staining methods. CeIIs were harvested when 100% of the cells were infected with ehrlichiae and were then pelleted in a centrifuge a t 17,000 x g for 20 min. Cell pellets were disrupted with a Braun-Sonic 2000 sonicator twice at 40W for 30 sec on ice. Ehrlichiae were purified as described previously (Weiss et al., 1975). The lysate was 1S loaded onto discontinuous gradients of 42%-36%-30% renografin, and centrifuged at 80,000 x g for 1 hr. Heavy and light bands containing ehrlichiae were collected and washed with sucrose-phosphate-glutamate buffer (SPG, 218 mM sucrose, 3.8 mM KHZP04, 7.2 m M
KZHP04, 4.9 mM glutamate, pH 7.0) and pelleted by centrifugation.
Nzcleic Acid Pr~arati~
Ehrlichia cams genomic DNA was prepared b y 2S resuspending the renografin-purified ehrlichiae in 600 p,l of i0 mM
Tris-HCl buffer (pH ?.S) with 1% sodium dodecyl sulfate (SDS, w/v) and i00 ng/ml of proteinase K as described previously (McBride et al., 1996). This mixture was incubated for 1 hr at S6° C, and the nucleic acids were extracted twice with a mixture o f phenol/chloroformlisoamyl alcohol {24:24:1). DNA was pelleted by absolute ethanol precipitation, washed once with 70% ethanol, dried and resuspended in l OmM Tris (pH 7.S). Plasmid DNA was purified b y using High Pure Plasmid Isolation Kit (Boehringer Mannheim, Indianapolis, IN), and PCR products were purified using a QIAquick PCR
S Purification Kit {Qiagen, Santa Clarita, CA).
PC'_R Amnlifica inn of the F cr~nis 2A-kIW nrn in CTPn,~e IO Regions of the E, canis ECa28-I gene selected for PCR
amplification were chosen based on homology observed (>90%) in the consensus sequence generated from Jotun-Hein aligorithm alignment of E. chaffeensis p28 and Cowdria ruminantium map-I genes. Forward primer 793 (S-GCAGGAGCTGTTGGTTACTC-3') (SEQ ID NO. 16) a n d 1 S reverse primer 1330 (S'-CCTTCCTCCAAGTTCTATGCC-3') (SEQ ID NO.
17) corresponded to nucleotides 313-332 and 823-843 of C.
ruminantium MAP-1 and 307-326 and 834-814 of E. chaffeensis P28.
E. canis (a North Carolina isolate, Jake) DNA was amplified with primers 793 and 1330 with a thermal cycling profile of 9S°C for 2 20 min, and 30 cycles of 9S°C for 30 sec, 62° C for 1 min, 72°C for 2 min followed by a 72°C extension for IO min and 4°C hold. PCR
products were analyzed on 1% agarose gels. This amplified PCR product was sequenced directly with primers 793 and 1330.
Primers specific for ECa28SA2 gene designated 46f (5' 2S ATATACTTCCTACCTAATGTCTCA-3', SEQ ID No. i 8) and primer 13 3 0 (SEQ ID No. 17) were used to amplify the targeted region. The amplified product was gel purified and cloned into a TA cloning vector {Invitrogen, Santa Clarita, CA). The clone was sequenced bidirectionally with primers: M13 reverse from the vector, 46f, 30 ECa28SA2 {S'-AGTGCAGAGTCTTCGGTTTC-3', SEQ ID No. 19), ECa5.3 (5'-GTTACTTGCGGAGGACAT-3', SEQ ID No. 20). DNA was amplified with a thermal cycling profile of 95°C for 2 min, and 30 cycles of 95°C
for 30 sec, 48°C for 1 min, 72°C for 1 min followed by a 72°C
extension for 10 min and 4°C hold.
~~g Llnkn~wn 5' ,~,~ Regions of ~k]'~e F.Ca2f3- I C'rene The full length sequence of ECa28-1 was determined using a Universal GenorneWalker Kit (CLONTECH, Palo Alto, CA) according t o the protocol supplied by the manufacturer. Genomic E. canis (Jake isolate) DNA was digested completely with five restriction enzymes (DraI, EcoRV, PvuII, ScaI, StuI) which produce blunt-ended DNA. An adapter (APl) supplied in the kit was ligated to each end of E. cams DNA. The genomic libraries were used as templates to find the unknown DNA sequence of the ECa28-1 gene by PCR using a primer complementary to a known portion of the ECa28-1 sequence and a primer specific for the adapter AP1. Primers specific for ECa28-1 a s a d for genome walking were designed from the known DNA s a q a a n c a derived from PCR amplification of ECa28-1 with primers 793 {SEQ ID
NO. 16) and 1330 (SEQ. ID NO. 17). Primers 394 (5'-GCATTTCCACAGGATCATAGGTAA-3'; nucleotides 687-7I0, SEQ ID NO.
2 I ) arid 394C (5'-TTACCTATGATCCTGT GGAAATGC-3; n a c 1 a o ti d a s 710-687, SEQ ID NO. 22) were used in conjunction with supplied primer APl to amplify the unknown 5' and 3' regions of the ECa28-1 gene by PCR. A PCR product corresponding to the 5' region of the ECa28-1 gene amplified with primers 3940 and AP1 {2000-bp) w,as sequenced unidirectionally with primer 793C (5'-GAGTA
ACCAACAGCTCCTGC-3', SEQ ID No. 23). A PCR product corresponding to the 3' region of the ECa28-1 gene amplified with primers 394 a n d APl (580-bp) was sequenced bidirectionally with the same primers.
Noncoding regions on the 5' and 3' regions adjacent to the open reading frame were sequenced, and primers EC280M-F (5'-TCTACTTTGCACTTCC ACTATTGT-3', SEQ ID NO. 24) and EC280M-R ( 5 ' -ATTCTITTGCCACTATTT TTCTTT-3', SEQ ID NO. 25) complementary t o these regions were designed in order to amplify the entire ECa28-1 gene.
E~ADZELE.~
y .~ncing ~f E.. rani.c isolates DNA was sequenced with an ABI Prism 377 DNA Sequencer {Perkin- Elmer Applied Biosystems, Foster City, CA). The entire Eca28 1 genes of seven E. canis isolates (four from North Carolina, and o n a each from Oklahoma, Florida, and Louisiana) were amplified by PCR
with primers EC280M-F (SEQ ID No. 24) and EC28OM-R (SEQ ID No.
25) with a thermal cycling profile of 95°C fox 5 minutes, and 30 cycles of 95°C for 30 seconds, 62°C for 1 minutes, and 72°C for 2 minutes and a 72°C extension for 10 minutes. The resulting PCR products were bidirectionally sequenced with the same primers.
f"'lons~lg and .xnregsion c~ F.. rani.c F. .a28-1 The entire E. canis ECa28-1 gene was PCR-amplified with primers-EC280M-F and EC280M-R and cloned into pCR2.l-TOPO TA
cloning vector to obtain the desired set of restriction enzyme cleavage sites (Invitrogen, Carlsbad, CA). The insert was excised from pCR2.1-TOPO with BstX 1 and ligated into pcDNA 3.1 eukaryotic expression vector {Invitrogen, Carlsbad, CA} designated pcDNA3.l/EC28 for subsequent studies. The pcDNA3.l/EC28 plasmid was amplified, a n d the gene. was excised with a KpnI-XbaI double digestion and directionally ligated into pThioHis prokaryotic expression vector (Invitrogen, Carlsbad, CA). The clone (designated pThioHis/EC28) produced a recombinant thioredoxin fusion protein in Escherichia coli BL21. The recombinant fusion protein was crudely purified in th a insoluble phase by centrifugation. The control thioredoxin fusion protein was purified from soluble cell lysates under native conditions using nickel-NTA spin columns (Qiagen, Santa Clarita, CA).
W~~ rn Im~n~h1 of ,u.al;rsi ss Recombinant E. canis ECa28-1 fusion protein was subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 4-15% Tris-HCl gradient gels (Bio-Rad, Hercules, CA) and transferred to pure nitrocellulose (Schleicher & Schuell, Keene, NH} using a semi-dry transfer cell (Bio-Rad, Hercules, CA). The membrane was incubated with convalescent phase antisera from an E. canis-infected dog diluted 1:5000 for 1 hour, washed, and then incubated with an anti-canine IgG
(H & L) alkaline phosphatase-conjugated affinity-purified secondary antibody at 1:1000 for I hour (Kirkegaard & Perry Laboratories, Gaithersburg, MD). Bound antibody was visualized with 5-bromo-4-chloro-3-indolyl phosphatelnitroblue tetrazolium (BCIP/NBT) substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD).

~nuthern ~IQt Analysis To determine if multiple genes homologous to the ECa28-I
gene were present in the E. canis genome, a genomic Southern blot analysis was performed using a standard procedure (Sambrook et al.
1989). E. canis genomic DNA digested completely with each of th a restriction enzymes BanII, EcoRV, HaeII, KpnI and SpeI, which do n o t cut within the ECa28-1 gene, and AseI which digests ECa28-I a t nucleotides 34, 43 and 656. The probe was produced by ~ PGR
amplification with primers EC284M-F and EC284M-R and digoxigenin {DIG)-labeled deoxynucleotide triphosphates {dNTPs) (Boehringer Mannheim, Indianapolis, IN) and digested with AseI. The digested probe (566-bp} was separated by agarose gel electrophoresis, gel-purified and then used for hybridization. The completely digested genomic E. canis DNA was electrophoresed and transferred to a nylon membrane (Boehringer Mannheim, Indianapolis, IN} and hybridized a t 40°C for 16 hr with the ECa28-1 gene DIG-labeled probe in DIG Easy Hyb buffer according to the manufacturer's protocol (Boehringer Mannheim, Indianapolis, IN). Bound probe was detected with a anti-DIG alkaline phosphatase-conjugated antibody and a luminescent substrate (Boehringer Mannheim, Indianapolis, IN) and exposed t o BioMax scientific imaging film (Eastman Kodak, Rochester, NY).
2 5 EXA P~dILF _9 ~n ~ .n . . Anal~~.c_L an C'.nmnarasinn E. chaffeensis p28 and C. rumi~cantium map-1 DNA
sequences were obtained from the National Center of Biotechnology information (NCBI) (World Wide Web site at URL:

http://www.ncbi.nlm.nih.gov/Entrez). Nucleotide and deduced amino acid sequences, and protein and phylogenetic analyses were performed with LASI~GINE software (DNASTAR, Inc., Madison, WI).
Analysis of post-translational processing was performed by the method of McGeoch and von Heijne for signal sequence recognition using the PSORT program (McGeoch, 1985; von Heijne, 1986) (World Wide Web site at URL: PRIVATE HREF "http:l/www.imcb.osaka-u.ac.jp/nakai/form.htm", MACROBUTTON HtmlResAnchor http:/lwww.imcb.osaka-u.ac.jp/nakai/form.htm).
GenBank accession numbers for nucleic acid and amino acid sequences of the E. canis ECa28-1 genes described in this study are: Jake, AF082744; Louisiana, AF082745; Oklahoma, AF082746;
Demon, AF082747; DJ, AF082748; Fuzzy, AF082749; Florida, AF082750.
Sequence analysis of ECa28-1 from seven different strains of E. canis was performed with primers designed to amplify the entire gene. Analysis revealed the sequence of this gene was conserved among the isolates from North Carolina (four), Louisiana, Florida a n d Oklahoma.
PC'R Amnlifica tOll~SlOnin~~llPnrttl~ and Fxnre~~i~n ~f FC'n~R 1 Alignment of nucleic acid sequences from E. chaffeensis p28 and Cowdria ruminantium map-1 using the Jotun-Hein aligorithm produced a consensus sequence with regions of high homology (>90%). These homologous regions (nucleotides 313-332 and 823-843 of C. ruminantium map-l; 307-326 and 814-834 of E. chaffeensis p28) were targeted as primer annealing sites for PCR amplification.
PCR amplification of the E. canis ECa28-I and E. chaffeensis p28 gene was accomplished with primers 793 and 1330, resulting in a 518-by PCR product. The nucleic acid sequence of the E. canis PCR product was obtained by sequencing the product directly with primers 793 and 1330. Analysis of the sequence revealed an open reading frame S encoding a protein of 170 amino acids, and alignment of the 518-by sequence obtained from PCR amplification of E. canis with the DNA
sequence of E. chaffeensis p28 gene revealed a similarity greater than 70°l0, indicating that the genes were homologous. Adapter PCR with primers 394 and 793C was performed to determine the 5' and 3 ' segments of the sequence of the entire gene. Primer 394 p r o d a c a d four PCR products (3-kb, 2-kb, 1-kb, and 0.8-kb), and the 0.8-by product was sequenced bidirectionally using primers 394 and AP1.
The deduced sequence overlapped with the 3' end of the 518-by product, extending the open reading frame 12-by to a termination codon. An additional 625-by of non-coding sequence at the 3' end o f the ECa28-1 gene was also sequenced. Primer 394C was used t o amplify the 5' end of the ECa28-1 gene with supplied primer AP1.
Amplification with these primers resulted in three PCR products (3.3, 3-kb, and 2-kb). The 2-kb fragment was sequenced unidirectionally with primer 793C. The sequence provided the putative start codon o f the ECa28-1 gene and completed the 834-by open reading frame encoding a protein of 278 amino acids. An additional 144-by o f readable sequence in the 5' noncoding region of the ECa28-I gene was generated. Primers EC280M-F and EC280M-R were designed from complementary non-coding regions adjacent to the ECa28-1 gene.
The PCR product amplified with these primers was sequenced directly with the same primers. The complete DNA
sequence (SE(~ ID NO. 1) for the E. canis ECa28-I gene is shown in Figure 1. The ECa28-1 PCR fragment amplified with these primers contained the entire open reading frame and 17 additional amino acids from the S' non-coding primer region. The gene was directionally subcloned into pThioHis expression vector, and E. coli (BL2I) were transformed with this construct. The expressed ECa28-1-thioredoxin fusion protein was insoluble. The expressed protein h ad S an additional 114 amino acids associated with the thioredoxin, S
amino acids for the enterokmase recognition site, and 32 amino acids from the multiple cloning site and S' non-coding primer region at the N-terminus. Convalescent-phase antiserum from an E. canis infected dog recognized the expressed recombinant fusion protein, but did n o t l0 react with the thioredoxin control (Figure 2).
~eq~~t~~~ce H~mologT
Z 5 The nucleic acid sequence of ECa28-1 (834-bp) and the E
chaffeensis omp-I family of genes including signal sequences (ECa28-1, omp-lA, B, G, D, E, and F) were aligned using the Clustal method t o examine homology between these genes (alignment not shown).
Nucleic acid homology was equally conserved (68.9%) between ECa28-20 l, and E. chaffeensis p28 and omp-1F. Other putative outer membrane protein genes in the E. chaffeensis omp-1 family, omp-1 D
(68.2%), omp-lE (66.7%), omp-1C (64.1%), Cowdria ruminantium map-I (61.8%), E. canis 28-kDa protein 1 gene (60%) and 28-kDa protein 2 gene (partial) {S9.S%) were also homologous to ECa28-1. E
25 chaffeensis omp-IB had the least nucleic acid homology {45:1%) with E.Ca28-1.
Alignment of the predicted amino acid sequences o f ECa28-1 (SEQ ID NO. 2) and E: chaffeensis P28 revealed amino acid substitutions resulting in four variable regions (VR). Substitutions o r 30 deletions in the amino acid sequence and the locations of variable regions of ECa28-1 and the E. chaffeensis OMP-1 family were identified (Figure 3}. Amino acid comparison including the signal peptide revealed that ECa28-1 shared the most homology with OMP-1F (68%) of the E. chaffeensis OMP-1 family, followed by E. chaffeensis P28 (65.5%), OMP-lE (65.1%), OMP-1D {62.9%), OMP-1C (62.9%), Cowdria runainantium MAP-1 (59.4%), E. canis 28-kDa protein 1 (55.6%) and 28-kDa protein 2 (partial) (53.6%), and OMP-1B
(43.2%). The phylogenetic relationships based on amino acid sequences show that ECa28-1 and C. ruminantium MAP-1, chaffeensis OMP-1 proteins, and E. cams 28-kDa proteins 1 and 2 (partial) are related (Figure 4).
Predicted ~nrfa . . Prnhahilit?~and TmmunnrPartivitv Analysis of E. canis ECa28-1 using hydropathy amd hydrophilicity profiles predicted surface-exposed regions on ECa28-1 (Figure 6). Eight major surface-exposed regions consisting of 3 to 9 amino acids were identified on ECa28-1 and were similar to the profile of surface-exposed regions on E. chaffeensis P28 {Figure 6}. Five o f the larger surface-exposed regions on ECa28-1 were located in the N-terminal region of the protein. Surface-exposed hydrophilic regions were found in all four of the variable regions of ECa28-1. Ten T-cell motifs were predicted in the ECa28-1 using the Rothbard-Taylor 2S aligorithm (Rothbard and Taylor, 1988), and high antigenicity of the ECa28-1 was predicted by the Jameson-Wolf antigenicity aligorithm (Figure 6) (Jameson and Wolf, 1988). Similarities in antigenicity and T-cell motifs were observed between ECa28-1 and E. chaffeensis P28.

Detection of Homoloøonc Cienomis C'~cnie-5 cf ~FC'a2R 1 C'T n Genomic Southern blot analysis of E. canis DNA completely digested independently with restriction enzymes BanII, EcoRV, HaeII, Kpni, SpeI, which do not have restriction endonuclease sites in the ECa28-1 gene, and AseI, which has internal restriction endonuclease sites at nucleotides 34, 43 and 656, revealed the presence of at least three homologous ECa28-1 gene copies (Figure 5). Although ECa28-1 has internal Ase I internal restriction sites, the DIG-labeled probe used in the hybridization experiment targeted a region of the gene within a single DNA fragment generated by the AseI digestion of the gene.
Digestion with AseI produced 3 bands (approximately 566-bp, 850 -bp, and 3-kb) that hybridized with the ECa28-1 DNA probe indicating the presence of multiple genes homologous to ECa28-1 in the genome.
Digestion with EcoRV and SpeI produced two bands that hybridized with the ECa28-1 gene probe.
Identification of 2R-kT~a Prnt in (''TPn I~~
Specific primers designated ECaSA3-2 (5'-CTAGGATTA
GGTTATAGTATAAGTT-3', SEQ ID No. 26) corresponding to regions within ECa28SA3 and primer 793C (SEQ ID No. 23) which anneals to a region with ECa28-1 were used to amplify the intergenic region between gene SA3 and ECa28-1. The 800-by product was sequenced with the same primers. DNA was amplified with a thermal cycling profile of 95°C for 2 min, and 30 cycles of 95°C fox 30 sec, 50°C for 1 min, 72°C for 1 min followed by a 72°C extension for 10 min and 4°C
hold.

WO 00l3274S f'CT/US99/28075 P_C'.R mnlific~tion cf 2f~-kDa Pro ein C; .n .s and Tdentificatinn ~f h a Mtlti.pje yen . .ocLs In order to specifically amplify possible unknown genes downstream of ECa28SA2, primer 4bf specific for ECa28SA2, a n d primer 1330 which targets a conserved region on the 3' end of ECa28-1 gene were used for amplification. A 2-kb PCR product was amplified with these primers that contained 2 open reading frames. The first open reading frame contained the known region of gene, ECaSA2, and a previously unsequenced 3' portion of the gene. Downstream from ECaSA2 an additional non identical, but homologous 28-kDa protein gene was found, and designated ECa28SA3. The two known loci were joined by amplification with primer SA3-2 specific for the 3' end o f ECa28SA3 gene was used in conjunction with a reverse primer 793C, which anneals at 5' end of ECa28-1. An 800-by PCR product was amplified which contained the 3' end of Eca28SA3, the intergenic region between ECa28SA3 and ECa28-I (28NC3) and the 5' end o f Eca28-1, joining the previously separate loci (Figure 8). The 849-by open reading frame of ECa28SA2 encodes a 283 amino acid protein, and ECa28SA3 has an 840-by open reading frame encoding a 2 8 0 amino acid protein. The intergenic noncoding region between ECa28SA3 and ECa28-1 was 345-by in length (Figures 7 and 8) 2 5 EXAMP_L L
jyLCleic and Amino Ar:~ Homolouv The nucleic and amino acid sequences of all five E. canis 28-kDa protein genes were aligned using the Clustal method t o examine the homology between these genes. The nucleic acid homology ranged from 58 to 75% and a similar amino acid homology of ranging from 67 to 72% was observed between the E. canis 28-kDa protein gene members (Figure 9).
EXA,D~ELE..1Z
Transcriptional Promo Pr ~gi~nc The intergenic regions between the 28-kDa protein genes were analyzed for promoter sequences by comparison with consensus Escherichia coli promoter regions and a promoter from E. chaffeensis (Yu et al., 1997; McClure, 1985).
Putative promoter sequences including RBS, -10 and - 3 5 regions were identified in 4 intergenic sequences corresponding t o genes ECa28SA2, ECa28SA3, ECa28-l, and ECa28-2 (Figure 10). The upstream noncoding region of ECa28SAl is not known and was n o t analyzed.
N-Terminal Signal ~ean_encP
The amino acid sequence analysis revealed that entire E.canis ECa28-1 has a deduced molecular mass of 30.5-kDa and the entire ECa28SA3 has a deduced molecular mass of 30.7-kDa. Both proteins have a predicted N-terminal signal peptide of 23 amino acids (MNCKKILITTALMSLMYYAPSIS, SEQ ID No. 27), which is similar to that predicted for E. chaffeensis P28 (IVINYKI~.,TTSALISLISSLPGV SFS, SEQ ID
NO. 28), and the OMP-1 protein family (Yu et al., 1998; Ohashi et al., 1998b). A preferred cleavage site for signal peptidases (SIS; Ser-X-Ser) (Oliver, 1985) is found at amino acids 21, 22, and 23 of ECa28-1.
An additional putative cleavage site at amino acid position 2 5 (MNCKKILITTALISLMYSIPSISSFS, SEQ ID NO. 29) identical to the predicted cleavage site of E. chaffeensis P28 (SFS) was also present, and would result in a mature ECa28-1 with a predicted molecular m a s s of 27.7-kDa. Signal cleavage site of the previously reported partial sequence of ECa28SA2 is predicted at amino acid 30. However, signal sequence analysis predicted that ECa28SA1 had an uncleavable signal sequence.
SLmmarv Proteins of similar molecular mass have been identified and cloned from multiple rickettsial agents including E. canis, E
chaffeensis, and C. ru»ainantium (Reddy et al., 1998; Jongejan et al., 1993; Ohashi et al., 1998}. A single locus in Ehrdichia chaffeensis with 6 homologous p28 genes, and 2 loci in E. canis, each containing some homologous 28-kDa protein genes have been previously described.
The present invention demonstrated the cloning, expression and characterization of genes encoding a mature 28-kDa protein of E. canis that are homologous to the omp-1 multiple gene family of E. chaffeensis and the C. ruminantium map-I gene. Two new 28-kDa protein genes were identidfied, Eca28-1 and ECa28SA3.
Another E.canis 28-kDa protein gene, ECa28SA2, partially sequenced previously (Reddy et al., 1998}, was sequenced completely in the present invention. Also disclosed is the identification and characterization of a single locus in E.canis containing ail five E.canis 28-kDa protein genes.
The E.canis 28-kDa protein are homologous to E.chaffeensis OMP-i family and the MAP-1 protein of C. rumanintium.
The most homologous E. cards 28-kDa proteins (ECa28SA3, ECa28-1 and ECa28-2) are sequentially arranged in the locus. Homology o f these proteins ranged from 67.5% to 72.3%. Divergence among these 28-kDa proteins was 27.3% to 38.6%. E. canis 28-kDa proteins ECa28SA1 and ECa28SA2 were the least homologous with homology ranging from 50.9% to 59.4% and divergence of 53.3 to 69.9%.
Differences between the genes lies primarily in the four hypervariable regions and suggests that these regions are surface exposed a n d subject to selective pressure by the immune system. Conservation o f ECa28-I among seven E. canis isolates has been reported (McBride a t al., 1999), suggesting that E.canis may be clonal in North America.
Conversely, significant diversity of p28 among E. chaffeensis isolates has been reported (Yu et al., 1998).
All of the E. canis 28-kDa proteins appear to be post translationally processed from a 30-kD protein to a mature 28-kD
protein. Recently, a signal sequence was identified on E. chaffeensis P28 {Yu et al., 1998), and N-terminal amino acid sequencing has verified that the protein is post-translationally processed resulting i n cleavage of the signal sequence to produce a mature protein (Ohashi et al., 1998). The leader sequences of OMP-1F and OMP-lE have also been proposed as leader signal peptides (Ohashi et ad., 1998). Signal sequences identified on E. chaffeensis OMP-1F, OMP-lE and P28 are homologous to the leader sequence of E. canis 28-kDa protein.
Promoter sequences for the p28 genes have not been determined experimentally, but putative promoter regions were identified b y comparison with consensus sequences of the RBS, -10 and -35 promoter regions of E. coli and other ehrlichiae (Yu et al., 1997;
McClure, 1985). Such promoter sequences would allow each gene t o potentially be transcribed and translated, suggesting that these genes may be differentially expressed in the host. Persistence of infection in dogs may be related to differential expression of p28 genes resulting in antigenic changes in vivo, thus allowing the organism to evade tha immune response.

The E. canis 28-kda protein genes were found to exhibit nucleic acid and amino acid sequence homology with the E
chaffeensis omp-1 gene family and C. ruminantiunz nzap-1 gene.
Previous studies have identified a 30-kDa protein of E canis that reacts with convalescent phase antisera against E chaffeensis, but was believed to be antigenically distinct (Rikihisa et al., 1994}. Findings based on comparison of amino acid substitutions in four variable regions of E. canis 28-kDa proteins support this possibility. Together these findings also suggest that the amino acids responsible for th a antigenic differences between E. canis and E, chaffeensis P28 are located in these variable regions and are readily accessible to the immune system. It was reported that immunoreactive peptides were located in the variable regions of the 28-kDa proteins of C.
ruminantium, E. chaffeensis and E. canis (Reddy et al., 1998). Analysis of E. canis and E. chaffeensis P28 revealed that all of the variable regions have predicted surface-exposed amino acids. A study in dogs demonstrated lack of cross protection between E. canis and E
chaffeensis (Dawson and Ewing, 1992). This observation may b a related to antigenic differences in the variable regions of P28 as well as in other immunologically important antigens of these ehrlichial species. Another study found that convalescent phase human antisera from E. chaffeensis-infected patients recognized 29/28-kDa proteins}
of E. chaffeensis and also reacted with homologous proteins of E. canis (Chen et al., 1997). Homologous and crossreactive epitopes on the E
cams 28-kDa protein and E chaffeensis P28 appear to be recognized by the immune system.
E. canis 28-kDa proteins may be important immunoprotective antigens. Several reports have demonstrated that the 30-kDa antigen of E canis exhibits strong immunoreactivity (Rikihisa et al., 1994; Rikihisa et al., 1992). Antibodies in convalescent phase antisera from humans and dogs have consistently reacted with proteins in this size range from E. chaffeensis and E
canis, suggesting that they may be important immunoprotective antigens (Rikihisa et al., 1994; Chen et al., 1994; Chen et al., I997). In addition, antibodies to 30, 24 and 21-kDa proteins developed early i n the immune response to E. canis (Rikihisa et al., 1994; Rikihisa et al., 1992), suggesting that these proteins may be especially important in the immune responses in the acute stage of disease. Recently, a family of homologous genes encoding outer membrane proteins with I 0 molecular masses of 28-kDa have been identified in E. chaffeensis, a n d mice immunized with recombinant E. chaffeensis P28 appeared t o have developed immunity against homologous challenge (Ohashi a t al., 1998). The P28 of E. chaffeensis has been demonstrated to b a present in the outer membrane, and immunoelectron microscopy has i 5 localized the P28 on the surface on the organism, and thus suggesting that it may serve as an adhesin {Ohashi et al., 1998). It is likely that the 28-kDa proteins of E. canis identified in this study have the s am a location and possibly serve a similar function.
Comparison of ECa28-1 from different strains of E. canis 20 revealed that the gene is apparently completely conserved. Studies involving E. chaffeensis have demonstrated immunologic and molecular evidence of diversity in the ECa28-1. Patients infected with E. chaffeensis have variable immunoreactivity to the 29/28-kDa proteins, suggesting that there is antigenic diversity (Chen et al., 25 1997). Recently molecular evidence has been generated to support antigenic diversity in the p28 gene from E. chaffeensis {Yu et al., 1998). A comparison of five E. chaffeensis isolates revealed that two isolates (Sapulpa and St. Vincent) were 100% identical, but three others (Arkansas, Sax, 9IHE17) were divergent by as much as 13.4%
30 at the amino acid Level. The conservation of ECa28-I suggests that E

canis strains found in the United States may be genetically identical, and thus E. canis 28-kDa protein is an attractive vaccine candidate f o r canine ehrlichiosis in the United States. Further analysis of E. canis isolates outside the United States may provide information regarding the origin and evolution of E. canis. Conservation of the 28-kDa protein makes it an important potential candidate for reliable serodiagnosis of canine ehrlichiosis.
The role of multiple homologous genes is not known a t this point; however, persistence of E.canis infections in dogs could conceivably be related to antigenic variation due to variable expression of homologous 28-kDa protein genes, thus enabling E
canis to evade immune surveillance. Variation of n2sp-3 genes in A.
marginale is partially responsible for variation in the MSP-3 protein, resulting in persistent infections (Alleman et al., 1997). Studies t o examine 28-kDa protein gene expression by E. canis in acutely and chronically infected dogs would provide insight into the role of the 28-kDa protein gene family in persistence of infection.
The following references were cited herein.
Alleman A.R., et al., (1997) Infect Irnmun 65: i56-163.
Anderson B.E., et al., (1991) J Clin Microbiol 29: 2838-2842.
Anderson B.E., et al., ( 1992) Int J Syst Bacteriol 42: 299-302.
Brouqui P., et al., ( 1992) J Clin Microbiol 30: 1062-1066.
Chen S.M., et al., ( 1997) Clin Diag Lab Immunol 4: 731-735.
Chen S.M., et al., (1994} Am J Trop Med Hyg 50: 52-58.
Dawson J.E., et aL, (1992) Am J Vet Res 53: 1322-1327.
Dawson J.E., et al., (1991) J Infect Dis 1b3: 564-567.
Donatien, et al., (1935) Bull Soc Pathol Exot 28: 418-9.
Swing, (1963) J Am Vet Med Assoc 143: 503-6.
Groves M.G., et al., ( 1975) Am J Vet Res 36: 937-940.
Harrus S., et al., (1998) J Clisa Microbiol 36: 73-76.

Jameson B.A., et al., ( 1988) CABIOS 4: 181-186.
Jongejan F., et al., (1993) Rev Elev Med Vet Pays Trop 46: 145-152.
McBride J.W., et al., {I996) J Vet Diag Invest 8: 441-447.
McBride; et al.,. ( 1999) Clin Diagn Lab Immunol.; (In press).
McCIure, (1985} Ann Rev Biochem 54: I71-204.
McGeoch D.J. (1985) Virus Res 3: 271-286.
Nyindo M., et al., {1991) Am J Vet Res 52: 1225-1230.
Nyindo, et al., (1971) Am J Vet Res 32: 1651-58.
Ohashi, et al., (1998) Infect Immun 66: 132-9.
Ohashi, et al., (1998} J Clin Microb 36: 2671-80 Reddy, et al., ( 1998) Biochem Biophys Res Comm 247: 636-43.
Rikihisa, et al., (1994) J Clin Microbiol32: 2107-12.
Rothbard J.B., et al., (1988) The EMBO J7: 93-100.
Sambrook J., et al., ( 1989) In Molecular Cloning: A Laboratory I5 Manual. Cold Spring Harbor: Cold Spring Harbor Press.
Troy G.C., et al., (1990} Canine ehrlichiosis. In Infectious diseases o f the dog and cat . Green C.E. (ed). Philidelphia: W.B. Sauders Co.
von Heijne, ( 1986) Nucl Acids Res I4: 4683-90.
Walker, et al., ( 1970) J Am Vet Med Assoc 157: 43-55.
Weiss E., et al., (1975) Appl Microbiol30: 456-463.
Yu, et al., (1997) Gene 184: 149-154.
Yu, et al.; ( 1998) J. Clin. Microbiol. (In press).
Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which tha invention pertains. These patents and publications are herein incorporated by reference to the same extent as if each individual publication was individually indicated to be incorporated b y reference.
One skilled in the art will readily appreciate that tha present invention is well adapted to carry out the objects and obtain the ends , and advantages mentioned, as well as those inherent therein.
The present examples along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention.
Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined b y the scope of the claims.

SEQUENCE LISTING
<110> Walker, David H.
McBride, Jere W.
Yu, Xue-Jie <120> Homologous 28-Kilodalton Immunodominant Protein Genes of Ehrlichia can.is and Uses Thereof <130> D6152PCT
<141> 1999-11-30 <150> 09/261,358 <151> 1999-03-03 <160> 33 <210> 1 <211> 1607 <212> DNA
<213> Ehrlichia cams <220>
<223> nucleic acid sequence of ECa28-1 <400> 1 attttattta ttaccaatct tatataatat attaaatttc tcttacaaaa 50 atctctaatg ttttatacct aatatatata ttctggcttg tatctacttt 100 gcacttccac tattgttaat ttattttcac tattttaggt gtaatatgaa 150 ttgcaaaaaa attcttataa caactgcatt aatatcatta atgtactcta 200 ttccaagcat atctttttct gatactatac aagatggtaa catgggtggt 250 aacttctata ttagtggaaa gtatgtacca agtgtctcac attttggtag 300 cttctcagct aaagaagaaa gcaaatcaac tgttggagtt tttggattaa 350 aacatgattg ggatggaagt ccaatactta agaataaaca cgctgacttt 400 actgttccaa actattcgtt cagatacgag aacaatccat ttctagggtt 450 tgcaggagct atcggttact caatgggtgg cccaagaata gaattcgaaa 500 tatcttatga agcattcgac gtaaaaagtc ctaatatcaa ttatcaaaat 550 gacgcgcaca ggtactgcgc tctatctcat cacacatcgg cagccatgga 600 agctgataaa tttgtcttct taaaaaacga agggttaatt gacatatcac 650 ttgcaataaa tgcatgttat gatataataa atgacaaagt acctgtttct 700 ccttatatat gcgcaggtat tggtactgat ttgatttcta tgtttgaagc 750 tacaagtcct aaaatttcct accaaggaaa actgggcatt agttactcta 800 ttaatccgga aacctctgtt ttcatcggtg ggcatttcca caggatcata 850 ggtaatgagt ttagagatat tcctgcaata gtacctagta actcaactac 900 aataagtgga ccacaatttg caacagtaac actaaatgtg tgtcactttg 950 gtttagaact tggaggaaga tttaacttct aattttattg ttgccacata 1000 ttaaaaatga tctaaacttg tttttawtat tgctacatac aaaaaaagaa 1050 aaatagtggc aaaagaatgt agcaataaga gggggggggg ggaccaaatt 1100 tatcttctat gcttcccaag ttttttcycg ctatttatga cttaaacaac 1150 agaaggtaat atcctcacgg aaaacttatc ttcaaatatt ttatttatta 1200 ccaatcttat ataatatatt aaatttctct tacaaaaatc actagtattt 1250 tataccaaaa tatatattct gacttgcttt tcttctgcac ttctactatt 1300 tttaatttat ttgtcactat taggttataa taawatgaat tgcmaaagat 1350 ttttcatagc aagtgcattg atatcactaa tgtctttctt acctagcgta 1400 tctttttctg aatcaataca tgaagataat ataaatggta acttttacat 1450 tagtgcaaag tatatgccaa gtgcctcaca ctttggcgta ttttcagtta 1500 aagaagagaa aaacacaaca actggagttt tcggattaaa acaagattgg 1550 gacggagcaa cactaaagga tgcaagcwgc agccacacaw tagacccaag 1600 tacaatg 1607 <210> 2 <211> 278 <212> PRT
<213> Ehriichia canis <220>
<223> amino acid sequence of ECa28-1 protein <400> 2 Met Asn Cys Lys Lys Ile Leu Ile Thr Thr Ala Leu Ile Ser Leu Met Tyr Ser Ile Pro Ser Ile Ser Phe Ser Asp Thr Ile Gln Asp Gly Asn Met Gly Gly Asn Phe Tyr Ile Ser Gly Lys Tyr Val Pro Ser Val Ser His Phe Gly Ser Phe Ser Ala Lys Glu Glu Ser Lys Ser Thr Val Gly Val Phe Gly Leu Lys His Asp Trp Asp Gly Ser Pro Ile Leu Lys Asn Lys His Ala Asp Phe Thr Val Pro Asn Tyr Ser Phe Arg Tyr Glu Asn Asn Pro Phe Leu Gly Phe Ala Gly Ala Ile Gly Tyr Ser Met Gly Gly Pro Arg Ile Glu Phe Glu Ile Ser WO 00/32745 PCT/US9912$07S
Tyr Glu Ala Phe Asp Val Lys Ser Pro Asn Ile Asn Tyr Gln Asn 125 1.30 135 Asp Ala His Arg Tyr Cys Ala Leu Ser His His Thr Ser Ala Ala Met Glu Ala Asp Lys Phe Val Phe Leu Lys Asn Glu Gly Leu Ile Asp Ile Ser Leu Ala Ile Asn Ala Cys Tyr Asp Ile Ile Asn Asp Lys Val Pro Val Ser Pro Tyr Ile Cys Ala Gly Ile Gly Thr Asp Leu Ile Ser Met Phe Glu Ala Thr Ser Pro Lys I1e Ser Tyr G1n Gly Lys Leu G1y Ile Ser Tyr Ser Ile Asn Pro Glu Thr Ser Val Phe Ile Gly Gly His Phe His Arg Ile I1e Gly Asn Glu Phe Arg Asp Tle Pro Ala Ile Val Pro Ser Asn Ser Thr Thr Ile Ser Gly Pro Gln Phe Ala Thr Val Thr Leu Asn Val Cys His Phe Gly Leu Glu Leu Gly Gly Arg Phe Asn Phe <210> 3 <211> 849 <212> DNA
<213> Ehrlichia can.is <220>
<221> mat_peptide <223> nucleic acid sequence of ECa28SA2 <400> 3 atgaattgta aaaaagtttt cacaataagt gcattgatat catccatata 50 cttcctacct aatgtctcat actctaaccc agtatatggt aacagtatgt 100 atggtaattt ttacatatca ggaaagtaca tgccaagtgt tcctcatttt 150 ggaatttttt cagctgaaga agagaaaaaa aagacaactg tagtatatgg 200 cttaaaagaa aactgggcag gagatgcaat atctagtcaa agtccagatg 250 ataattttac cattcgaaat tactcattca agtatgcaag caacaagttt 300 WO OEl/32745 PCT/US99/28U75 ttagggtttg cagtagctat tggttactcg ataggcagtc caagaataga 350 agttgagatg tcttatgaag catttgatgt gaaaaatcca ggtgataatt 400 acaaaaacgg tgcttacagg tattgtgctt tatctcatca agatgatgcg 450 gatgatgaca tgactagtgc aactgacaaa tttgtatatt taattaatga 500 aggattactt aacatatcat ttatgacaaa catatgttat gaaacagcaa 550 gcaaaaatat acctctctct ccttacatat gtgcaggtat tggtactgat 600 ttaattcaca tgtttgaaac tacacatcct aaaatttctt atcaaggaaa 650 gctagggttg gcctacttcg taagtgcaga gtcttcggtt tcttttggta 700 tatattttca taaaattata aataataagt ttaaaaatgt tccagccatg 750 gtacctatta actcagacga gatagtagga ccacagtttg caacagtaac 800 attaaatgta tgctactttg gattagaact tggatgtagg ttcaacttc 849 <210> 4 <211> 283 <212> PRT
<213> Ehrlichia canis <220>
<223> amino acid sequence of ECa28SA2 protein <400> 4 Met Asn Cys Lys Lys Val Phe Thr Ile Ser Ala Leu Ile Sex Ser Ile Tyr Phe Leu Pro Asn Val Ser Tyr Ser Asn Pro Val Tyr Gly Asn Ser Met Tyr Gly Asn Phe Tyr Ile Ser Gly Lys Tyr Met Pro Ser Val Pro His Phe Gly Ile Phe Ser Ala Glu Glu Glu Lys Lys Lys Thr Thr Val Val Tyr Gly Leu Lys Glu Asn Trp Ala Gly Asp Ala Ile Ser Ser Gln Ser Pro Asp Asp Asn Phe Thr Ile Arg Asn Tyr Ser Phe Lys Tyr Ala Ser Asn Lys Phe Leu Gly Phe Ala Val Ala Ile Gly Tyr Ser Ile Gly Ser Pro Arg Ile Glu Val Glu Met Ser Tyr Glu A1a Phe Asp Val Lys Asn Pro Gly Asp Asn Tyr Lys Asn Gly Ala Tyr Arg Tyr Cys Ala Leu Ser His Gln Asp Asp Ala Asp Asp Asp Met Thr Ser Ala Thr Asp Lys Phe Val Tyr Leu Ile Asn Glu Gly Leu Leu Asn Ile Ser Phe Met Thr Asn Ile Cys Tyr Glu Thr A1a Ser Lys Asn Ile Pro Leu Ser Pro Tyr Tle Cys Ala Gly I1e Gly Thr Asp Leu Ile His Met Phe Glu Thr Thr His Pro zoo 205 210 Lys Ile Ser Tyr Gln Gly Lys Leu Gly Leu Ala Tyr Phe Val Ser A1a Glu Ser Ser Val Ser Phe Gly Ile Tyr Phe His Lys Ile I1e Asn Asn Lys Phe Lys Asn Val Pro Ala Met Va1 Pro Ile Asn Ser Asp Glu Ile Val Gly Pro Gln Phe Ala Thr Val Thr Leu Asn Val Cys Tyr Phe Gly Leu Glu Leu Giy Cys Arg Phe Asn Phe <210> 5 <211> 840 <212> DNA
<213> Ehrlichia canis <220>
<221> mat_peptide <223> nucleic acid sequence of ECa28SA3 <400> 5 atgaattgca aaaaaattct tataacaact gcattaatgt cattaatgta 50 ctatgctcca agcatatctt tttctgatac tatacaagac gataacactg 100 gtagcttcta catcagtgga aaatatgtac caagtgtttc acattttggt 150 gttttctcag ctaaagaaga aagaaactca actgttggag tttttggatt 200 aaaacatgat tggaatggag gtacaatatc taactcttct ccagaaaata 250 tattcacagt tcaaaattat tcgtttaaat acgaaaacaa cccattctta 300 gggtttgcag gagctattgg ttattcaatg ggtggcccaa gaatagaact 350 tgaagttctg tacgagacat tcgatgtgaa aaatcagaac aataattata 400 agaacggcgc acacagatac tgtgctttat ctcatcatag ttcagcaaca 450 agcatgtcct ccgcaagtaa caaatttgtt ttcttaaaaa atgaagggtt 500 aattgactta tcatttatga taaatgcatg ctatgacata ataattgaag 550 gaatgccttt ttcaccttat atttgtgcag gtgttggtac tgatgttgtt 600 tccatgtttg aagctataaa tcctaaaatt tcttaccaag gaaaactagg 650 attaggttat agtataagtt cagaagcctc tgtttttatc ggtggacact 700 ttcacagagt cataggtaat gaatttagag acatccctgc tatggttcct 750 agtggatcaa atcttccaga aaaccaattt gcaatagtaa cactaaatgt 800 gtgtcacttt ggcatagaac ttggaggaag atttaacttc 840 <210> 6 <211> 280 <212> PRT
<213> Ehrlichia caxsis <220>
<223> amino acid sequence of ECa28SA3 protein <400> 6 Met Asn Cys Lys Lys Ile Leu I1e Thr Thr Ala Leu Met Ser Leu Met Tyr Tyr Ala Pro Ser Ile Ser Phe Ser Asp Thr Ile Gln Asp Asp Asn Thr Gly Ser Phe Tyr Ile Ser G1y Lys Tyr Val Pro Ser Val Ser His Phe Gly Val Phe Ser Ala Lys G1u Glu Arg Asn Ser Thr Val Gly Va1 Phe Gly Leu Lys His Asp Trp Asn Gly Gly Thr Ile Ser Asn Ser Ser Pro Glu Asn Ile Phe Thr VaI GLn Asn Tyr Ser Phe Lys Tyr Glu Asn Asn Pro Phe Leu Gly Phe Ala Gly Ala Ile Gly Tyr Ser Met Gly Gly Pro Arg Tle Glu Leu Glu Val Leu Tyr Glu Thr Phe Asp Val Lys Asn Gln Asn Asn Asn Tyr Lys Asn Gly Ala His Arg Tyr Cys Ala Leu Ser His His Ser Ser Ala Thr Ser Met Ser Ser Ala Ser Asn Lys Phe Val Phe Leu Lys Asn Glu Gly Leu Ile Asp Leu Ser Phe Met Ile Asn Ala Cys Tyr Asp Tle Ile Ile Glu Gly Met Pro Phe Ser Pro Tyr Ile Cys Ala Gly Val Gly Thr Asp Val Val Ser Met Phe Glu Ala Ile Asn Pro Lys Ile Ser Tyr Gln Gly Lys Leu Gly Leu Gly Tyr Ser Ile Ser Ser Glu Ala Ser Val Phe Ile Gly Gly His Phe His Arg Val Ile Gly Asn Glu Phe Arg Asp Ile Pro Ala Met Val Pro Ser Gly Ser Asn Leu Pro Glu Asn Gln Phe Ala Ile Val Thr Leu Asn Val Cys His Phe Gly Ile Glu Leu Gly G1y Arg Phe Asn Phe <210> 7 <211> 133 <212> PRT
<213> Ehrlichia canis <220>
<223> partial amino acid sequence of ECa28SA2 protein <400> 7 Met Asn Cys Lys Lys Val Phe Thr Ile Ser Ala Leu Ile Ser Ser Ile Tyr Phe Leu Pro Asn Val Ser Tyr Ser Asn Pro Val Tyr Gly Asn Ser Met Tyr Gly Asn Phe Tyr Ile Ser Gly Lys Tyr Met Pro Ser Val Pro His Phe Gly Ile Phe Ser Ala Glu G1u Glu Lys Lys Lys Thr Thr Val Val Tyr Gly Leu Lys G1u Asn Trp Ala Gly Asp Ala Ile Ser Ser Gln Ser Pro Asp Asp Asn Phe Thr Ile Arg Asn Tyr Ser Phe Lys Tyr Ala Ser Asn Lys Phe Leu Gly Phe Ala Val Ala Ile Gly Tyr Ser Ile Gly Ser Pro Arg Ile Glu Val Glu Met Ser Tyr G1u Ala Phe Asp Val Lys Asn Gln Gly Asn Asn <210> 8 <211> 287 <212> PRT
<213> Ehr.~icliia cams <220>
<223> amino acid sequence of ECa28SA1 protien <400> 8 Met Lys Tyr Lys Lys Thr Phe Thr Val Thr Ala Leu Val Leu Leu Thr Ser Phe Thr His Phe Ile Pro Phe Tyr Ser Pro Ala Arg Ala Ser Thr Ile His Asn Phe Tyr Ile Ser G1y Lys Tyr Met Pro Thr Ala Ser His Phe Gly Ile Phe Ser Ala Lys Glu Glu Gln Ser Phe Thr Lys Val Leu Val Gly Leu Asp Gln Arg Leu Ser His Asn Ile Ile Asn Asn Asn Asp Thr Ala Lys Ser Leu Lys Val Gln Asn Tyr Ser Phe Lys Tyr Lys Asn Asn,Pro Phe Leu Gly Phe Ala Gly Ala Ile Gly Tyr Ser Ile Gly Asn Ser Arg Ile Glu Leu Glu Val Ser His Giu Ile Phe Asp Thr Lys Asn Pro Gly Asn Asn Tyr Leu Asn Asp Ser His Lys Tyr Cys Ala Leu Ser His Gly Ser His Ile Cys Ser Asp Gly Asn Ser Gly Asp Trp Tyr Thr Ala Lys Thr Asp Lys Phe Val Leu Leu Lys Asn Glu Gly Leu Leu Asp Val Ser Phe Met Leu Asn Ala Cys Tyr Asp Ile Thr Thr Glu Lys Met Pro Phe Ser Pro Tyr Ile Cys Ala Gly Ile Gly Thr Asp Leu Ile Ser Met Phe Glu Thr Thr Gln Asn Lys Ile Ser Tyr Gln Gly Lys Leu Gly Leu Asn Tyr Thr Ile Asn Ser Arg Val Ser Val Phe Ala Gly Gly His Phe His Lys Val Ile G1y Asn Glu Phe Lys G1y Ile Pro Thr Leu Leu Pro Asp Gly Ser Asn Ile Lys Va1 Gln Gln Ser Ala Thr Val Thr Leu Asp Val Cys His Phe Gly Leu Glu Ile Gly Ser Arg Phe Phe Phe <210> 9 <211> 281 <212> PRT
<213> Ehrlichia chaffeensis <220>
<223> amino acid sequence of E. chaffeensis P28 <400> 9 Met Asn Tyr Lys Lys Val Phe Ile Thr Ser Ala Leu Ile Ser Leu Ile Ser Ser Leu Pro Gly Val Ser Phe Ser Asp Pro Ala Gly Ser Gly Ile Asn Gly Asn Phe Tyr Ile Ser G1y Lys Tyr Met Pro Ser Ala Ser His Phe Gly Val Phe Ser Ala Lys Glu Glu Arg Asn Thr Thr Val Gly Va1 Phe G1y Leu Lys Gln Asn Trp Asp G1y Ser Ala Ile Ser Asn Ser Ser Pro Asn Asp Val Phe Thr Val Ser Asn Tyr Ser Phe Lys Tyr Glu Asn Asn Pro Phe Leu Gly Phe Ala Gly Ala WO 00132745 PCTIUS99l28075 Ile Gly Tyr Ser Met Asp Gly Pro Arg Ile Glu Leu Glu Val Ser Tyr Glu Thr Phe Asp Val Lys Asn Gln Gly Asn Asn Tyr Lys Asn Glu Ala His Arg Tyr Cys Ala Leu Ser His Asn Ser Ala Ala Asp Met Ser Ser Ala Ser Asn Asn Phe Val Phe Leu Lys Asn Glu Gly Leu Leu Asp Ile Ser Phe Met Leu Asn Ala Cys Tyr Asp Val Val Gly Glu Gly I1e Pro Phe Ser Pro Tyr Ile Cys Ala Gly Ile Gly Thr Asp Leu Val Ser Met Phe Glu Ala Thr Asn Pro Lys Ile Ser Tyr Gln Gly Lys Leu Gly Leu Ser Tyr Ser I1e Sex Pro Glu Ala Ser Val Phe Ile Gly Gly His Phe His Lys Val Ile Gly Asn Glu Phe Arg Asp Ile Pro Thr Ile Ile Pro Thr Gly Ser Thr Leu Ala Gly Lys Gly Asn Tyr Pro Ala Ile Val Ile Leu Asp Val Cys His Phe Gly Tle Glu Leu Gly Gly Arg Phe A1a Phe <210> 10 <221> 283 <212> PRT
<213> Ehrlichia chaffeensis <220>
<223> amino acid sequence of E. chaffeensis OMP-1B
<400> 10 Met Asn Tyr Lys Lys Ile Phe Val Ser Ser Ala Leu Ile Ser Leu Met Ser Ile Leu Pro Tyr Gln Ser Phe Ala Asp Pro Val Thr Ser Asn Asp Thr Gly Ile Asn Asp Ser Arg Glu Gly Phe Tyr Ile Ser Val Lys Tyr Asn Pro Ser Ile Ser His Phe Arg Lys Phe Ser Ala Glu Glu Ala Pro I1e Asn Gly Asn Thr Ser I1e Thr Lys Lys Val Phe Gly Leu Lys Lys Asp Gly Asp I1e Ala Gln Ser Ala Asn Phe so s5 90 Asn Arg Thr Asp Pro Ala Leu Glu Phe Gln Asn Asn Leu Ile Ser Gly Phe Ser Gly Ser Ile Gly Tyr Ala Met Asp Gly Pro Arg Ile Glu Leu Glu Ala Ala Tyr Gln Lys Phe Asp Ala Lys Asn Pro Asp Asn Asn Asp Thr Asn Ser Gly Asp Tyr Tyr Lys Tyr Phe Gly Leu Ser Arg Glu Asp Ala Ile Ala Asp Lys Lys Tyr Val Val Leu Lys Asn Glu Gly Ile Thr Phe Met Ser Leu Met Va1 Asn Thr Cys Tyr Asp Ile Thr Ala Glu Gly Val Pro Phe Ile Pro Tyr Ala Cys Ala Gly Val G1y Ala Asp Leu Ile Asn Val Phe Lys Asp Phe Asn Leu Lys Phe Ser Tyr Gln Gly Lys Ile Gly Ile Ser Tyr Pro Tle Thr Pro Glu Val Ser Ala Phe Ile,Gly Gly Tyr Tyr His Gly Val Ile Gly Asn Asn Phe Asn Lys Ile Pro Val Ile Thr Pro Val Val Leu Glu Gly Ala Pro Gln Thr Thr Ser Ala Leu Val Thr Ile Asp Thr Gly Tyr Phe Gly Gly Glu Val Gly Val Arg Phe Thr Phe <210> 11 <211> 280 <212> PRT
<213> .Ehrlichia chaffeensis <220>
<223> amino acid sequence of E. chaffeensis OMP-1C
<400> 11 Met Asn Cys Lys Lys Phe Phe Ile Thr Thr Ala Leu Ala Leu Pro Met Ser Phe Leu Pro G1y Ile Leu Leu Ser Glu Pro Val Gln Asp Asp Ser Val Ser Gly Asn Phe Tyr Ile Ser Gly Lys Tyr Met Pro Ser Ala Ser His Phe Gly Val Phe Ser Ala Lys Glu Glu Lys Asn Pro Thr Val Ala Leu Tyr Gly Leu Lys Gln Asp Trp Asn Gly Val Ser Ala Ser Ser His Ala Asp Ala Asp Phe Asn Asn Lys Gly Tyr Ser Phe Lys Tyr Glu Asn Asn. Pro Phe Leu Gly Phe A1a Gly Ala Ile Gly Tyr Sex Met Gly Gly Pro Arg Ile Glu Phe Glu VaI Ser Tyr Glu Thr Phe Asp Val Lys Asn Gln Gly Gly Asn Tyr Lys Asn Asp Ala His Arg Tyr Cys Ala Leu Asp Arg Lys Ala Ser Ser Thr Asn Ala Thr Ala Ser His Tyr Val Leu Leu Lys Asn Glu Gly Leu Leu Asp Ile Ser Leu Met Leu Asn Ala Cys Tyr Asp Val Va1 Ser 170 175 ~ 180 Glu Gly Ile Pro Phe Ser Pro Tyr Ile Cys Ala Gly Val Gly Thr Asp Leu Ile Ser Met Phe Glu Ala Ile Asn Pro Lys Iie Ser Tyr Gln Gly Lys Leu Gly Leu Ser Tyr Ser Ile Asn Pro Glu Ala Ser Val Phe Val Gly Gly His Phe His Lys Val Ala Gly Asn Glu Phe WO 00132745 PCT/US99l2$075 Arg Asp Ile Ser Thr Leu Lys A1a Phe Ala Thr Pro Ser Ser Ala A1a Thr Pro Asp Leu Ala Thr Val Thr Leu Ser Va1 Cys His Phe Gly Val Glu Leu Gly Gly Arg Phe Asn Phe <210> 12 <211> 286 <212> PRT
<213> Ehrlichia chaffeensis <220>
<223> amino acid sequence of E. chaffeensis OMP-1D
<400> 12 Met Asn Cys Glu Lys Phe Phe Ile Thr Thr Ala Leu Thr Leu Leu Met Ser Phe Leu Pro Gly I1e Ser Leu Ser Asp Pro Val Gln Asp Asp Asn Ile Ser Gly Asn Phe Tyr Ile Ser Gly Lys Tyr Met Pro Ser Ala Ser His Phe Gly Va1 Phe Ser Ala Lys Glu Glu Arg Asn Thr Thr Val Gly Val Phe Gly Ile Glu Gln Asp Trp Asp Arg Cys Val Ile Ser Arg Thr Thr Leu Ser Asp Ile Phe Thr Val Pro Asn Tyr Ser Phe Lys Tyr Glu Asn Asn Leu Phe Ser Gly Phe Ala Gly Ala Ile Gly Tyr Ser Met Asp G1y Pro Arg Tle Glu Leu Glu Val Ser Tyr Glu Ala Phe Asp Val Lys Asn Gln Gly Asn Asn Tyr Lys Asn Glu Ala His Arg Tyr Tyr Ala Leu Ser His Leu Leu Gly Thr Glu Thr Gln Ile Asp Gly Ala Gly Ser Ala Ser Val Phe Leu Ile SEQ 13!24 Asn Glu Gly Leu Leu Asp Lys Ser Phe Met Leu Asn Ala Cys Tyr Asp Val Ile Ser Glu Gly Ile Pro Phe Ser Pro Tyr Ile Cys Ala Gly Ile Gly Ile Asp Leu Val Ser Met Phe G1u A1a Ile Asn Pro Lys Ile Ser Tyr Gln Gly Lys Leu Gly Leu Ser Tyr Pro I1e Ser Pro Glu Ala Ser Val Phe Ile Gly Gly His Phe His Lys Val Ile Gly Asn Glu Phe Arg Asp Ile Pro Thr Met Lle Pro Ser Glu Ser Ala Leu A1a Gly Lys Gly Asn Tyr Pro Ala Ile Val Thr Leu Asp Val Phe Tyr Phe Gly Ile Glu Leu Gly Gly Arg Phe Asn Phe Gln Leu <210> 13 <211> 278 <212> PRT
<213> Eh.rlichia chaffeensis <220>
<223> amino acid sequence of E. chaffeensis OMP-1E
<400> 13 Met Asn Cys Lys Lys Phe Phe Ile Thr Thr Ala Leu Val Ser Leu Met Sex Phe Leu Pro Gly I3.e Ser Phe Ser Asp Pro Val Gln Gly Asp Asn Ile Ser Gly Asn Phe Tyr Val Ser Gly Lys Tyr Met Pro Ser A1a Ser His Phe Gly Met Phe Ser Ala Lys Glu Glu Lys Asn Pro Thr Val Ala Leu Tyr Gly Leu Lys Gln Asp Trp Glu Gly Ile Ser Ser Ser Ser His Asn Asp Asn His Phe Asn Asn Lys Gly Tyr Ser Phe Lys Tyr Glu Asn Asn Pro Phe Leu Gly Phe Ala Gly Ala Ile G1y Tyr Ser Met Gly Gly Pro Arg Val Glu Phe Glu Val Ser Tyr Glu Thr Phe Asp Val Lys Asn Gln G1y Asn Asn Tyr Lys Asn Asp Ala His Arg Tyr Cys Ala Leu Gly Gln Gln Asp Asn Ser Gly Ile Pro Lys Thr Ser Lys Tyr Val Leu Leu Lys Ser Glu Gly Leu Leu Asp Ile Ser Phe Met Leu Asn Ala Cys Tyr Asp Ile Ile Asn Glu Ser Ile Pro Leu Ser Pro Tyr Ile Cys Ala Gly Val Gly Thr Asp Leu Ile Ser Met Phe Glu Ala Thr Asn Pro Lys Ile Ser Tyr Gln Gly Lys Leu Gly Leu Ser Tyr Ser Ile Asn Pro Glu Ala Ser Val Phe Tle Gly Gly His Phe His Lys Val Ile Gly Asn Glu Phe Arg Asp Ile Pro Thr Leu Lys Ala Phe Val Thr Ser Ser Ala Thr Pro Asp Leu Ala Ile Val Thr Leu Ser Val Cys His Phe Gly Ile Glu Leu Gly Gly Arg Phe Asn Phe <210> 14 <211> 280 <212> PRT
<213> Ehrlichia chaffeensis <220>
<223> amino acid sequence of E. chaffeensis OMP-1F
<400> 14 Met Asn Cys Lys Lys Phe Phe Ile Thr Thr Thr Leu Val Ser Leu Met Ser Phe Leu Pro Gly IleSer PheSer Asp Ala Val Gln Asn Asp Asn Val Gly Gly Asn PheTyr IleSer Gly Lys Tyr Val Pro Ser Val Ser His Phe G1y Va1Phe SerAla Lys Gln Glu Arg Asn Thr Thr Thr Gly Val Phe GlyLeu LysGln Asp Trp Asp Gly Ser Thr Ile Ser Lys Asn Ser ProGlu AsnThr Phe Asn Val Pro Asn Tyr Ser Phe Lys Tyr Glu AsnAsn ProPhe Leu Gly Phe Ala Gly Ala Val Gly Tyr Leu Met AsnGly ProArg Ile Glu Leu Glu Met Ser Tyr Glu Thr Phe Asp ValLys AsnGln Gly Asn Asn Tyr Lys Asn Asp Ala His Lys Tyr TyrAla LeuThr His Asn Ser Gly Gly Lys Leu Ser Asn Ala Gly AspLys PheVal Phe Leu Lys Asn G1u Gly Leu Leu Asp Ile Ser LeuMet LeuAsn Ala Cys Tyr Asp Val Ile Ser Glu Gly Ile Pro PheSer ProTyr I1e Cys Ala Gly Val Gly Thr Asp Leu Ile Ser MetPhe GluAla Ile Asn Pro Lys Ile Ser Tyr Gln Gly Lys Leu GlyLeu SerTyr Ser Ile Ser Pro Glu Ala Ser Val Phe Va1 Gly GlyHis PheHis Lys Val Ile Gly Asn Glu Phe Arg Asp Ile Pro AlaMet IlePro Ser Thr Ser Thr Leu Thr Gly Asn His Phe Thr IleVa1 ThrLeu Ser Val Cys His Phe Gly Val Glu Leu Gly Gly Phe Phe Arg Asn <210> 15 <211> 284 <212> PRT
<213> Cowdria ruminantium <220>
<223> amino acid sequence of C. ruminantium MAP-1 <400> 15 Met Asn Cys Lys Lys Ile Phe Ile Thr Ser Thr Leu Ile Ser Leu Val Ser Phe Leu Pro Gly Val Ser Phe Ser Asp Val Ile Gln Glu Glu Asn Asn Pro Val Gly Ser Val Tyr Ile Ser Ala Lys Tyr Met Pro Thr A1a Ser His Phe Gly Lys Met Ser Ile Lys Glu Asp Ser Arg Asp Thr Lys Ala Val Phe Gly Leu Lys Lys Asp Trp Asp Gly Val Lys Thr Pro Ser Gly Asn Thr Asn Ser Ile Phe Thr Glu Lys Asp Tyr Ser Phe Lys Tyr Glu Asn Asn Pro Phe Leu Gly Phe Ala g5 100 105 Gly Ala Val Gly Tyr Ser Met Asn Gly Pro Arg Ile Glu Phe Glu Val Ser Tyr Glu Thr Phe Asp Val Arg Asn Pro Gly GIy Asn Tyr Lys Asn Asp Ala His Met Tyr Cys Ala Leu Asp Thr Ala Ser Ser Ser Thr Ala Gly Ala Thr Thr Ser Val Met Val Lys Asn Glu Asn Leu Thr Asp IIe Ser Leu Met Leu Asn Ala Cys Tyr Asp I1e Met Leu Asp Gly Met Pro Val Ser Pro Tyr Val Cys Ala Gly IIe Gly Thr Asp Leu Val Ser Val Tle Asn Ala Thr Asn Pro Lys Leu Ser Tyr Gln Gly Lys Leu Gly Ile Ser Tyr Ser Ile Asn Pro Glu Ala Ser Ile Phe Ile Gly Gly His Phe His Arg Val Ile Gly Asn Glu Phe Lys Asp Ile Ala Thr Ser Lys Val Phe Thr Ser Ser Gly Asn Ala Ser Ser Ala Val Ser Pro Gly Phe Ala Ser Ala Ile Leu Asp Val Cys His Phe Gly Ile Glu Ile Gly Gly Arg Phe Val Phe <210> 16 <211> 20 <212> DNA
<2I3> artificial sequence <220>
<221> primer bind <222> nucleotides 313-332 of C. ruminantium MAP-2, also nucleotides 307-326 of E. chaffeensis P28 <223> forward primer 793 for PCR
<400> 16 gcaggagctg ttggttactc 20 <210> 17 <221> 21 <212> DNA
<213> artificial sequence <220>
<221> primer-bind <222> nucleotides 823-843 of C. ruminantium MAP-Z, also nucleotides 814-834 of E. chaffeensis P28 <223> reverse primer 1330 for PCR
<400> 17 ccttcctcca agttctatgc c 21 <210> 18 <211> 24 <212> DNA

<213> artificial sequence <220>
<221> primer_bind <223> primer 46f, specific for ECa28SA2 gene <400> 18 atatacttcc tacctaatgt ctca 24 <210> 19 <211> 20 <212> DNA
<213> artificial sequence <220>
<221> primer_bind <223> primer used for sequencing 28-kDa protein genes in E. canis <400> 19 agtgcagagt cttcggtttc 20 <210> 20 <211> 18 <212> DNA
<213> artificial sequence <220>
<221> primer_bind <223> primer used for sequencing 28-kDa protein genes in E. cams <400> 20 gttacttgcg gaggacat 1g <210> 21 <221> 24 <212> DNA

<213> artificial sequence <220>

<221> primer band <222> nucleotides 687-710 of ECa28-2 WO 00/32?45 PCT/US99128075.
<223> primer 394 for PCR
<400> 21 gcatttccac aggatcatag gtaa 24 <210> 22 <211> 24 <212> DNA

<213> artificial sequence <220>

<221> primer_band <222> nucleotides 710-687 of ECa28-2 <223> primer 394C for PCR

<400> 22 ttacctatga tcctgtggaa atgc 24 <210> 23 <211> 20 <212> DNA
<213> artificial sequence <220>
<221> primer_bind <223> primer 793C which anneals to a region with Eca28-1, used to amplify the intergenic region between gene ECa28SA3 and ECa28-1 <400> 23 gagtaaccaa cagctcctgc 20 <210> 24 <211> 24 <212> DNA
<213> artificial sequence <220>
<221> primer band <222>
<223> primer EC280M-F complementary to noncoding regions adjacent to the open reading frame of ECa28-.Z
<400> 24 tctactttgc acttccacta ttgt 24 <210> 25 <211> 24 <212> DNA
<213> artificial sequence <220>
<221> primer_band <223> primer EC280M-R complementary to noncoding regions adjacent to the open reading frame of ECa28-1 <400> 25 attcttttgc cactattttt cttt 24 <210> 26 <211> 25 <212> DNA
<213> artificial sequence <220>
<221> primer_bind <223> primer ECaSA3-2 corresponding to regions within ECa28SA3,used to amplify the intergenic region NC3 between gene ECa28SA3 and ECa28-1 <400> 26 ctaggattag gttatagtat aagtt 25 <210> 27 <211> 23 <212> PRT

<213 Ehrlichia cani s >

<220>

<221> PEPTIDE

<223> a predicted N-terminal signal peptide of ECa28-1 and ECa28SA3 <400> 27 Met Asn Cys Lys Lys Ile Leu Ile Thr Thr Ala Leu Met Ser Leu Met Tyr Tyr Ala Pro Ser Ile Ser <210> 28 <211> 25 <212> PRT
<213> Ehrlichia chaffeensis <220>
<223> amino acid sequence of N-terminal signal peptide of E. chaffeensis P28 <400> 28 Met Asn Tyr Lys Lys Ile Leu Ile Thr Ser Ala Leu I1e Ser Leu Ile Ser Ser Leu Pro Gly Va1 Ser Phe Ser <210> 29 <211> 2G
<212> PRT
<213> Ehrlichia canis <220>
<223> amino acid sequence of putative cleavage site of ECa28-1 <400> 29 Met Asn Cys Lys Lys Ile Leu Ile Thr Thr Ala Leu Ile Ser Leu Met Tyr Ser Ile Pro Ser Lle Ser Ser Phe Ser <210> 30 <211> 299 <212> DNA
<213> Ehrlichia canis <220>
<223> nucleic acid sequence of intergenic noncoding region 1 (28NC1) <400> 30 taatacttct attgtacatg ttaaaaatag tactagtttg cttctgtggt 50 ttataaacgc aagagagaaa tagttagtaa taaattagaa agttaaatat 100 tagaaaagtc atatgttttt cattgtcatt gatactcaac taaaagtagt 150 ataaatgtta cttattaata attttacgta gtatattaaa tttcccttac 200 aaaagccact agtattttat actaaaagct atactttggc ttgtatttaa 250 tttgtatttt tactactgtt aatttacttt cactgtttct ggtgtaaat 299 <210> 31 <211> 345 <212> DNA
<213> Ehrlichia cams <220>
<223> nucleic acid sequence of intergenic noncoding region 2 {28NC2) <400> 31 taatttcgtg gtacacatat cacgaagcta aaattgtttt tttatctctg 50 ctgtatacaa gagaaaaaat agtagtgaaa attacctaac aatatgacag 100 tacaagttta ccaagcttat tctcacaaaa cttcttgtgt cttttatctc 150 tttacaatga aatgtacact tagcttcact actgtagagt gtgtttatca 200 atgctttgtt tattaatact ctacataata tgttaaattt ttcttacaaa 250 actcactagt aatttatact agaatatata ttctgacttg tatttgcttt 300 atacttccac tattgttaat ttattttcac tattttaggt gtaat 345 <210> 32 <211> 345 <212> DNA
<213> Ehrlichia cams <220>
<223> nucleic acid sequence of intergenic noncoding region 3 { 2 8NC3 ) <400> 32 tgattttatt gttgccacat attaaaaatg atctaaactt gtttttatta 50 ttgctacata caaaaaaaag aaaaatagtg gcaaaagaat gtagcaataa 100 gagggggggg ggggactaaa tttaccttct attcttctaa tattctttac 150 tatattcaaa tagcacaact caatgcttcc aggaaaatat gtttctaata 200 ttttatttat taccaatcct tatataatat attaaatttc tcttacaaaa 250 atctctaatg ttttatactt aatatatata ttctggcttg tatttacttt 300 gcacttccac tattgttaat ttattttcac tattttaggt gtaat 345 <210> 33 <211> 355 <212> DNA
<213> Ehrlichia cams <220>
<223> nucleic acid sequence of intergenic noncoding region 4 (28NC4) <400> 33 taattttatt gttgccacat attaaaaatg atctaaactt gtttttawta 50 ttgctacata caaaaaaaga aaaatagtgg caaaagaatg tagcaataag 100 aggggggggg gggaccaaat ttatcttcta tgcttcccaa gttttttcyc 150 gctatttatg acttaaacaa cagaaggtaa tatcctcacg gaaaacttat 200 cttcaaatat tttatttatt accaatctta tataatatat taaatttctc 250 ttacaaaaat cactagtatt ttataccaaa atatatattc tgacttgctt 300 ttcttctgca cttctactat ttttaattta tttgtcacta ttaggttata 350 ataaw 355

Claims

WHAT IS CLAIMED IS:
1. DNA sequences encoding a 30-kilodalton protein of Ehrlichia canis, wherein said protein is immunoreactive with anti-Ehrlichia canis serum, and wherein said protein has an amino acid sequence selected from the group consisting of SEQ ID No. 4 and SEQ
ID No. 6.
3. The DNA sequences of claim 1, wherein said protein has as N-terminal signal sequence.
4. The DNA sequences of claim 3, wherein said protein is post-translationally modified to a 28-kilodalton protein.
5. The DNA sequences of claim 1, wherein said DNA
has a sequence selected from the group consisting of SEQ ID No. 3 and SEQ ID No. 5.
6. A vector comprising the DNA sequences of claim 1.

7. The DNA sequences of claim 6, wherein said locus is a multigene locus of 5.592 kb in length.
8. The DNA sequences of claim 7, wherein said locus encoding homologous 28-kilodalton proteins of Ehrlichia cantis.
9. The DNA sequences of claim 8, wherein said homologous 28-kilodalton proteins of Ehrlichia canis are selected from the group consisting of ECa28SA1, ECa28SA2, ECa28SA3, ECa28-1 and ECa28-2.
10. A vector comprising the DNA sequences of claim 1.
11. The vector of claim 10, wherein said vector is an expression vector capable of expressing a peptide or polypeptide encoded by the sequence selected from the group consisting of SEQ ID
No. 1, SEQ ID No. 3 and SEQ ID No. 5 when said expression vector is introduced into a cell.
12. A recombinant protein comprising the amino acid sequence selected from the group consisting of SEQ ID No. 2, SEQ ID
No. 4 and SEQ ID No. 6.
13. The recombinant protein of claim 12, wherein said amino acid sequence is encoded by a nucleic acid segment comprising a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID
No. 3 and SEQ ID No. 5.
14. A host cell comprising the nucleic acid segment selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5.
15. A method of producing the recombinant protein of claim 12, comprising the steps of:
obtaining a vector that comprises an expression region comprising a sequence encoding the amino acid sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID
No. 6 operatively linked to a promoter;
transfecting said vector into a cell; and culturing said cell under conditions effective for expression of said expression region.
16. An antibody immunoreactive with an amino acid sequence selected from the group consisting of SEQ ID No. 4 and SEQ
ID No. 6.
17. A method of inhibiting Ehrlichia canis infection in a subject comprising the steps of:
identifying a subject suspected of being exposed to or infected with Ehrlichia canis; and ' administering a composition comprising a 28-kDa antigen of Ehrlichia canis in an amount effective to inhibit an Ehrlichia canis infection.
18. The method of claim 17, wherein said 28-kDa antigen is a recombinant protein comprising an amino acid sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6.
19. The method of claim 18, wherein said recombinant protein is encoded by a gene comprising a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5.
20. The method of claim 18, wherein said recombinant protein is dispersed in a pharmaceutically acceptable carrier.